Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists

ABSTRACT

The invention relates to benzimidazole-carboxamide 5-HT 4  receptor agonist compounds of formula (I) 
                         
wherein R 1  and X are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT 4  receptor activity, and processes and intermediates useful for preparing such compounds.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.15/956,958, filed Apr. 19, 2018, now allowed, which is a continuation ofU.S. application Ser. No. 15/221,841, filed Jul. 28, 2016, (now U.S.Pat. No. 9,975,877), which is a continuation of U.S. application Ser.No. 14/488,520, filed Sep. 17, 2014 (now U.S. Pat. No. 9,428,489 B2),which is a continuation of U.S. application Ser. No. 13/742,783, filedJan. 16, 2013 (now Abandoned), which is a divisional of U.S. applicationSer. No. 12/796,902, filed Jun. 9, 2010 (now U.S. Pat. No. 8,377,964B2), which is a divisional of U.S. application Ser. No. 11/439,671,filed May 24, 2006 (now U.S. Pat. No. 7,759,363 B2), which claims thebenefit of U.S. Provisional Applications Nos. 60/684,466 and 60/684,478,filed on May 25, 2005, and 60/748,415, filed on Dec. 8, 2005, thedisclosures of which are incorporated herein by reference in theirentirety.

BACKGROUND OF THE INVENTION Field of the Invention

The invention is directed to benzimidazole-carboxamide compounds whichare useful as 5-HT₄ receptor agonists. The invention is also directed topharmaceutical compositions comprising such compounds, methods of usingsuch compounds for treating or preventing medical conditions mediated by5-HT₄ receptor activity, and processes and intermediates useful forpreparing such compounds.

State of the Art

Serotonin (5-hydroxytryptamine, 5-HT) is a neurotransmitter that iswidely distributed throughout the body, both in the central nervoussystem and in peripheral systems. At least seven subtypes of serotoninreceptors have been identified and the interaction of serotonin withthese different receptors is linked to a wide variety of physiologicalfunctions. There has been, therefore, substantial interest in developingtherapeutic agents that target specific 5-HT receptor subtypes.

In particular, characterization of 5-HT₄ receptors and identification ofpharmaceutical agents that interact with them has been the focus ofsignificant recent activity. (See, for example, the review by Langloisand Fischmeister, J. Med. Chem. 2003, 46, 319-344.) 5-HT₄ receptoragonists are useful for the treatment of disorders of reduced motilityof the gastrointestinal tract. Such disorders include irritable bowelsyndrome (IBS), chronic constipation, functional dyspepsia, delayedgastric emptying, gastroesophageal reflux disease (GERD), gastroparesis,post-operative ileus, intestinal pseudo-obstruction, and drug-induceddelayed transit. In addition, it has been suggested that some 5-HT₄receptor agonist compounds may be used in the treatment of centralnervous system disorders including cognitive disorders, behavioraldisorders, mood disorders, and disorders of control of autonomicfunction.

Despite the broad utility of pharmaceutical agents modulating 5-HT₄receptor activity, few 5-HT₄ receptor agonist compounds are in clinicaluse at present. Accordingly, there is a need for new 5-HT₄ receptoragonists that achieve their desired effects with minimal side effects.Preferred agents may possess, among other properties, improvedselectivity, potency, pharmacokinetic properties, and/or duration ofaction.

SUMMARY OF THE INVENTION

The invention provides novel compounds that possess 5-HT₄ receptoragonist activity. Among other properties, compounds of the inventionhave been found to be potent and selective 5-HT₄ receptor agonists. Inaddition, preferred compounds of the invention have been found toexhibit favorable pharmacokinetic properties in an animal model whichare predictive of good bioavailability upon oral administration.

Accordingly, the invention provides a compound of formula (I):

wherein:

R¹ is C₃₋₅alkyl, optionally substituted with —OH; and

X is selected from

-   -   (a) —C(O)OR² wherein R² is C₁₋₄alkyl or —(CH₂)_(n)-phenyl        wherein n is 0 or 1;    -   (b) —C(O)R³ wherein R³ is selected from:        -   phenyl, optionally substituted with 1, 2, or 3 substituents            selected from C₁₋₄alkyl, halo, C₁₋₄alkoxy, —CF₃, —OCF₃,            —OCHF₂, and —CN,        -   C₁₋₅alkyl,        -   C₄₋₅cycloalkyl, and        -   —(CH₂)_(m)-A wherein m is 0 or 1 and A is selected from            amino, furanyl, thiophenyl, morpholinyl, tetrahydrofuranyl,            pyridinyl, naphthalenyl, pyrrolyl, thiomorpholinyl,            pyrrolidinyl, piperidinyl, oxoazetidinyl, thiazolidinyl,            1,1-dioxo isothiazolidinyl, and 2,4-dimethylisoxazolyl;    -   (c) —C(O)NR⁴R⁵ wherein R⁴ is hydrogen or C₁₋₃alkyl, and R⁵ is        phenyl optionally substituted with 1, 2, or 3 substituents        selected from C₁₋₄alkyl, halo, C₁₋₄alkoxy, —CF₃, —OCF₃, and        —OCHF₂;    -   (d) —C(O)C(R⁶R⁷)R⁸ wherein R⁶ is hydrogen or C₁₋₃alkyl and R⁷ is        hydrogen, —OH, or C₁₋₃alkyl; or R⁶ and R⁷ taken together form        oxo or —(CH₂)₂—; and R⁸ is phenyl or cyclohexyl, wherein phenyl        or cyclohexyl are optionally substituted with 1, 2, or 3        substituents selected from C₁₋₄alkyl, halo, C₁₋₄alkoxy, —CF₃,        —OCF₃, —OCHF₂, and —CN;    -   (e) —C(O)C(HR⁹)OR¹⁰ wherein R⁹ is hydrogen or C₁₋₃alkyl, and R¹⁰        is phenyl optionally substituted with 1, 2, or 3 substituents        selected from C₁₋₄alkyl, halo, C₁₋₄alkoxy, —CF₃, —OCF₃, and        —OCHF₂; and    -   (f) —S(O)₂R¹¹ wherein R¹¹ is selected from C₁₋₃alkyl,        —CH₂-phenyl, furanyl, thiophenyl, morpholinyl,        tetrahydrofuranyl, pyridinyl, naphthalenyl, pyrrolyl,        thiomorpholinyl, pyrrolidinyl, piperidinyl, oxoazetidinyl,        thiazolidinyl, 1,1-dioxo isothiazolidinyl,        2,4-dimethylisoxazolyl, and phenyl optionally substituted with        1, 2, or 3 substituents selected from C₁₋₄alkyl, halo,        C₁₋₄alkoxy, —CF₃, —OCF₃, —OCHF₂, and —CN;

or a pharmaceutically-acceptable salt or solvate or stereoisomerthereof.

The invention also provides a pharmaceutical composition comprising acompound of the invention and a pharmaceutically-acceptable carrier.

In another aspect, the invention provides a method of treating a diseaseor condition associated with 5-HT₄ receptor activity, e.g. a disorder ofreduced motility of the gastrointestinal tract, the method comprisingadministering to the mammal, a therapeutically effective amount of acompound of the invention.

Further, the invention provides a method of treating a disease orcondition associated with 5-HT₄ receptor activity in a mammal, themethod comprising administering to the mammal, a therapeuticallyeffective amount of a pharmaceutical composition of the invention.

The compounds of the invention can also be used as research tools, i.e.to study biological systems or samples, or for studying the activity ofother chemical compounds. Accordingly, in another of its method aspects,the invention provides a method of using a compound of formula (I), or apharmaceutically acceptable salt or solvate or stereoisomer thereof, asa research tool for studying a biological system or sample or fordiscovering new 5-HT₄ receptor agonists, the method comprisingcontacting a biological system or sample with a compound of theinvention and determining the effects caused by the compound on thebiological system or sample.

In separate and distinct aspects, the invention also provides syntheticprocesses and intermediates described herein, which are useful forpreparing compounds of the invention.

The invention also provides a compound of the invention as describedherein for use in medical therapy, as well as the use of a compound ofthe invention in the manufacture of a formulation or medicament fortreating a disease or condition associated with 5-HT₄ receptor activity,e.g. a disorder of reduced motility of the gastrointestinal tract, in amammal.

DETAILED DESCRIPTION OF THE INVENTION

The invention provides novel benzimidazole-carboxamide 5-HT₄ receptoragonists of formula (I), or pharmaceutically-acceptable salts orsolvates or stereoisomers thereof. The following substituents and valuesare intended to provide representative examples of various aspects ofthis invention. These representative values are intended to furtherdefine such aspects and are not intended to exclude other values orlimit the scope of the invention.

In a specific aspect of the invention, R¹ is C₃₋₅alkyl, optionallysubstituted with —OH.

In another specific aspect, R¹ is C₃₋₅alkyl.

In other specific aspects, R¹ is C₃₋₄alkyl; or R¹ is isopropyl ortert-butyl.

In another specific aspect, R¹ is isopropyl.

In yet other specific aspects, R¹ is 1-hydroxy-1-methylethyl, or2-hydroxy-1-methylethyl.

In a specific aspect, X is —C(O)OR² wherein R² is C₁₋₄alkyl or—(CH₂)_(n)-phenyl wherein n is 0 or 1.

In another specific aspect, X is —C(O)OR² wherein R² is C₁₋₃alkyl orphenyl.

In other specific aspects, X is —C(O)OR² wherein R² is methyl or phenyl,or wherein R² is methyl.

In a specific aspect, X is —C(O)R³ wherein R³ is selected from phenyl,optionally substituted with 1, 2, or 3 substituents selected fromC₁₋₄alkyl, halo, C₁₋₄alkoxy, —CF₃, —OCF₃, —OCHF₂, and —CN; C₁₋₅alkyl;C₄₋₅cycloalkyl; and —(CH₂)_(m)-A wherein m is 0 or 1 and A is selectedfrom amino, furanyl, thiophenyl, morpholinyl, tetrahydrofuranyl,pyridinyl, naphthalenyl, pyrrolyl, thiomorpholinyl, pyrrolidinyl,piperidinyl, oxoazetidinyl, thiazolidinyl, 1,1-dioxo isothiazolidinyl,and 2,4-dimethylisoxazolyl.

In another specific aspect, X is —C(O)R³ wherein R³ is phenyl,optionally substituted with 1, 2, or 3 substituents selected fromC₁₋₄alkyl, halo, C₁₋₄alkoxy, —CF₃, —OCF₃, —OCHF₂, and —CN.

In another specific aspect, X is —C(O)R³ wherein R³ is C₁₋₅alkyl orC₄₋₅cycloalkyl.

In another specific aspect, X is —C(O)R³ wherein R³ is —(CH₂)_(m)-Awherein m is 0 and A is selected from amino, furanyl, thiophenyl,morpholinyl, tetrahydrofuranyl, pyridinyl, naphthalenyl, pyrrolyl,thiomorpholinyl, pyrrolidinyl, piperidinyl, oxoazetidinyl,thiazolidinyl, 1,1-dioxo isothiazolidinyl, and 2,4-dimethylisoxazolyl.

In another specific aspect, X is —C(O)R³ wherein R³ is phenyl,optionally substituted with 1 or 2 substituents selected from C₁₋₄alkyl,halo, and —CF₃; furanyl; or thiophenyl.

In yet other specific aspects, X is —C(O)R³ wherein R³ is phenyloptionally substituted with 1 or 2 substituents selected from methyl,chloro, fluoro, and —CF₃; or R³ is furan-2-yl or thiophen-2-yl.

In a specific aspect, X is —C(O)NR⁴R⁵ wherein R⁴ is hydrogen orC₁₋₃alkyl, and R⁵ is phenyl optionally substituted with 1, 2, or 3substituents selected from C₁₋₄alkyl, halo, C₁₋₄alkoxy, —CF₃, —OCF₃, and—OCHF₂.

In another specific aspect, X is —C(O)NR⁴R⁵ wherein R⁴ is hydrogen.

In another specific aspect, X is —C(O)NR⁴R⁵ wherein R⁴ is hydrogen andR⁵ is phenyl optionally substituted with 1 or 2 substituents selectedfrom C₁₋₄alkyl and halo.

In other specific aspects, X is —C(O)NR⁴R⁵ wherein R⁴ is hydrogen and R⁵is phenyl optionally substituted with 1 halo, or with one fluoro orchloro.

In a specific aspect, X is —C(O)C(R⁶R⁷)R⁸ wherein R⁶ is hydrogen orC₁₋₃alkyl and R⁷ is hydrogen, —OH, or C₁₋₃alkyl; or R⁶ and R⁷ takentogether form oxo or —(CH₂)₂—; and R⁸ is phenyl or cyclohexyl, whereinphenyl or cyclohexyl are optionally substituted with 1, 2, or 3substituents selected from C₁₋₄alkyl, halo, C₁₋₄alkoxy, —CF₃, —OCF₃,—OCHF₂, and —CN.

In another specific aspect, X is —C(O)C(R⁶R⁷)R⁸ wherein R⁶ is hydrogen.

In another specific aspect, X is —C(O)C(R⁶R⁷)R⁸ wherein R⁸ is phenyloptionally substituted with 1, 2, or 3 substituents selected fromC₁₋₄alkyl, halo, C₁₋₄alkoxy, —CF₃, —OCF₃, —OCHF₂, and —CN.

In another specific aspect, X is —C(O)C(R⁶R⁷)R⁸ wherein R⁸ is cyclohexyloptionally substituted with 1, 2, or 3 substituents selected fromC₁₋₄alkyl, halo, C₁₋₄alkoxy, —CF₃, —OCF₃, —OCHF₂, and —CN.

In yet other specific aspects, X is —C(O)C(R⁶R⁷)R⁸ wherein R⁶ ishydrogen and R⁷ is hydrogen, —OH, or methyl; or R⁶ and R⁷ taken togetherform oxo or —(CH₂)₂—; and R⁸ is phenyl or cyclohexyl, wherein phenyl orcyclohexyl are optionally substituted with 1 or 2 substituents selectedfrom C₁₋₄alkyl and halo; or R⁸ is phenyl or cyclohexyl, wherein phenylor cyclohexyl are optionally substituted with 1 or 2 substituentsselected from methyl, fluoro, and chloro.

In a specific aspect, X is —C(O)C(HR⁹)OR¹⁰ wherein R⁹ is hydrogen orC₁₋₃alkyl, and R¹⁰ is phenyl optionally substituted with 1, 2, or 3substituents selected from C₁₋₄alkyl, halo, C₁₋₄alkoxy, —CF₃, —OCF₃, and—OCHF₂.

In another specific aspect, X is —C(O)C(HR⁹)OR¹⁰ wherein R⁹ is hydrogenor methyl.

In other specific aspects, X is —C(O)C(HR⁹)OR¹⁰ wherein R⁹ is hydrogenor methyl and R¹⁰ is phenyl optionally substituted with 1 or 2substituents selected from C₁₋₄alkyl and halo, or phenyl optionallysubstituted with 1 or 2 substituents selected from methyl, fluoro, andchloro.

In a specific aspect, X is —S(O)₂R¹¹ wherein R¹¹ is selected fromC₁₋₃alkyl, —CH₂-phenyl, furanyl, thiophenyl, morpholinyl,tetrahydrofuranyl, pyridinyl, naphthalenyl, pyrrolyl, thiomorpholinyl,pyrrolidinyl, piperidinyl, oxoazetidinyl, thiazolidinyl, 1,1-dioxoisothiazolidinyl, 2,4-dimethylisoxazolyl, and phenyl optionallysubstituted with 1, 2, or 3 substituents selected from C₁₋₄alkyl, halo,C₁₋₄alkoxy, —CF₃, —OCF₃, —OCHF₂, and —CN.

In another specific aspect, X is —S(O)₂R¹¹ wherein R¹¹ is C₁₋₃alkyl,2,4-dimethylisoxazolyl, or phenyl, optionally substituted with 1, 2, or3 substituents selected from C₁₋₄alkyl, halo, C₁₋₄alkoxy, —CF₃, —OCF₃,—OCHF₂, and —CN.

In other specific aspects, X is —S(O)₂R¹¹ wherein R¹¹ is methyl orphenyl optionally substituted with 1 or 2 substituents selected fromC₁₋₄alkyl and halo; or with 1 or 2 substituents selected from methyl,fluoro, and chloro.

In one aspect, the invention provides a compound of formula (I) wherein

R¹ is C₃₋₄alkyl; and

X is selected from:

-   -   (a) —C(O)OR² wherein R² is C₁₋₃alkyl or phenyl;    -   (b) —C(O)R³ wherein R³ is phenyl, optionally substituted with 1        or 2 substituents selected from C₁₋₄alkyl, halo, and —CF₃;        furanyl; or thiophenyl;    -   (c) —C(O)NR⁴R⁵ wherein R⁴ is hydrogen and R⁵ is phenyl        optionally substituted with 1 or 2 substituents selected from        C₁₋₄alkyl and halo;    -   (d) —C(O)C(R⁶R⁷)R⁸ wherein R⁶ is hydrogen and R⁷ is hydrogen,        —OH, or methyl; or R⁶ and R⁷ taken together form oxo or        —(CH₂)₂—; and R⁸ is phenyl or cyclohexyl, wherein phenyl or        cyclohexyl are optionally substituted with 1 or 2 substituents        selected from C₁₋₄alkyl and halo;    -   (e) —C(O)C(HR⁹)OR¹⁰ wherein R⁹ is hydrogen or methyl and R¹⁰ is        phenyl optionally substituted with 1 or 2 substituents selected        from C₁₋₄alkyl and halo; and    -   (f) —S(O)₂R¹¹ wherein R¹¹ is methyl or phenyl, optionally        substituted with 1 or 2 substituents selected from C₁₋₄alkyl and        halo.

The invention further provides a compound of formula (I) wherein:

R¹ is isopropyl or tert-butyl; and

X is selected from:

-   -   (a) —C(O)OR² wherein R² is methyl or phenyl;    -   (b) —C(O)R³ wherein R³ is phenyl, optionally substituted with 1        or 2 substituents selected from methyl, chloro, fluoro, and        —CF₃; furan-2-yl; or thiophen-2-yl; and    -   (c) —C(O)NR⁴R⁵ wherein R⁴ is hydrogen and R⁵ is phenyl        optionally substituted with 1 fluoro or chloro.

In still other specific aspects, the invention provides the compoundslisted in the Examples and in Tables I to IX below.

The chemical naming convention used herein is illustrated for thecompound of Example 1:

which is designated4-(4-{[(2-isopropyl-1H-benzoimidazole-4-carbonyl)amino]methyl}-piperidin-1-ylmethyl)piperidine-1-carboxylicacid methyl ester, according to the AutoNom software, provided by MDLInformation Systems, GmbH (Frankfurt, Germany). The fused ring structure“benzoimidazole” is alternatively named “benzimidazole”. The two termsare equivalent as used herein.

As exemplified by particular compounds listed in the tables below, thecompounds of the invention may contain a chiral center. Accordingly, theinvention includes racemic mixtures, pure stereoisomers, andstereoisomer-enriched mixtures of such isomers, unless otherwiseindicated. When a particular stereoisomer is shown, it will beunderstood by those skilled in the art, that minor amounts of otherstereoisomers may be present in the compositions of the invention unlessotherwise indicated, provided that any utility of the composition as awhole is not eliminated by the presence of such other isomers.

In one aspect, the invention provides a compound selected from:

-   4-(4-{[(2-isopropyl-1H-benzoimidazole-4-carbonyl)-amino]methyl}piperidin-1-ylmethyl)piperidine-1-carboxylic    acid methyl ester;-   4-(4-{[(2-isopropyl-1H-benzoimidazole-4-carbonyl)-amino]-methyl}piperidin-1-ylmethyl)piperidine-1-carboxylic    acid phenyl ester;-   2-isopropyl-1H-benzoimidazole-4-carboxylic acid    {1-[1-(2-chlorobenzoyl) piperidin-4-ylmethyl]    piperidin-4-ylmethyl}amide;-   2-isopropyl-1H-benzoimidazole-4-carboxylic acid    {1-[1-(2,4-difluoro-benzoyl)piperidin-4-ylmethyl]piperidin-4-ylmethyl}amide;-   2-isopropyl-1H-benzoimidazole-4-carboxylic acid    {1-[1-(furan-2-carbonyl)-piperidin-4-ylmethyl]piperidin-4-ylmethyl}amide;-   2-isopropyl-1H-benzoimidazole-4-carboxylic acid    {1-[1-(thiophene-2-carbonyl)piperidin-4-ylmethyl]piperidin-4-ylmethyl}amide;-   2-isopropyl-1H-benzoimidazole-4-carboxylic acid    {1-[1-(2-fluoro-5-trifluoromethylbenzoylpiperidin-4-ylmethyl]piperidin-4-ylmethyl}amide;-   2-isopropyl-1H-benzoimidazole-4-carboxylic acid    {1-[1-(2-fluoro-phenylcarbamoyl)piperidin-4-ylmethyl]piperidin-4-ylmethyl}-amide;-   4-(4-{[(2-tert-butyl-1H-benzoimidazole-4-carbonyl)-amino]-methyl}piperidin-1-ylmethyl)piperidine-1-carboxylic    acid methyl ester;-   2-tert-butyl-1H-benzoimidazole-4-carboxylic acid    {1-[1-(2-fluoro-benzoyl)-piperidin-4-ylmethyl]piperidin-4-ylmethyl}amide;-   2-tert-butyl-1H-benzoimidazole-4-carboxylic acid    {1-[1-(3-methyl-benzoyl)-piperidin-4-ylmethyl]piperidin-4-ylmethyl}amide;    and-   2-tert-butyl-1H-benzoimidazole-4-carboxylic acid    {1-[1-(4-fluorobenzoyl)-piperidin-4-ylmethyl]piperidin-4-ylmethyl}amide.

Definitions

When describing the compounds, compositions and methods of theinvention, the following terms have the following meanings, unlessotherwise indicated.

The term “alkyl” means a monovalent saturated hydrocarbon group whichmay be linear or branched or combinations thereof. Unless otherwisedefined, such alkyl groups typically contain from 1 to 10 carbon atoms.Representative alkyl groups include, by way of example, methyl (Me),ethyl, n-propyl (n-Pr), isopropyl (iPr), n-butyl (n-Bu), sec-butyl,isobutyl, tert-butyl (tBu), n-pentyl, n-hexyl, n-heptyl, n-octyl,n-nonyl, n-decyl and the like.

The term “alkoxy” means a monovalent group —O-alkyl, where alkyl isdefined as above. Representative alkoxy groups include, by way ofexample, methoxy, ethoxy, propoxy, butoxy, and the like.

The term “cycloalkyl” means a monovalent saturated carbocyclic groupwhich may be monocyclic or multicyclic. Unless otherwise defined, suchcycloalkyl groups typically contain from 3 to 10 carbon atoms.Representative cycloalkyl groups include, by way of example,cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,cyclooctyl, and the like.

The term “halo” means fluoro, chloro, bromo or iodo.

The term “oxo” means a double-bonded oxygen atom (═O).

The term “compound” means a compound that was synthetically prepared orproduced in any other way, such as by metabolism.

The term “therapeutically effective amount” means an amount sufficientto effect treatment when administered to a patient in need of treatment.

The term “treatment” as used herein means the treatment of a disease,disorder, or medical condition in a patient, such as a mammal(particularly a human) which includes:

-   -   (a) preventing the disease, disorder, or medical condition from        occurring, i.e., prophylactic treatment of a patient;    -   (b) ameliorating the disease, disorder, or medical condition,        i.e., eliminating or causing regression of the disease,        disorder, or medical condition in a patient;    -   (c) suppressing the disease, disorder, or medical condition,        i.e., slowing or arresting the development of the disease,        disorder, or medical condition in a patient; or    -   (d) alleviating the symptoms of the disease, disorder, or        medical condition in a patient.

The term “pharmaceutically-acceptable salt” means a salt prepared froman acid or base which is acceptable for administration to a patient,such as a mammal. Such salts can be derived frompharmaceutically-acceptable inorganic or organic acids and frompharmaceutically-acceptable bases. Typically,pharmaceutically-acceptable salts of compounds of the present inventionare prepared from acids.

Salts derived from pharmaceutically-acceptable acids include, but arenot limited to, acetic, adipic, benzenesulfonic, benzoic,camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic,hydrobromic, hydrochloric, lactic, maleic, malic, mandelic,methanesulfonic, mucic, nitric, pantothenic, phosphoric, succinic,sulfuric, tartaric, p-toluenesulfonic, xinafoic (1-hydroxy-2-naphthoicacid), naphthalene-1,5-disulfonic acid and the like.

The term “solvate” means a complex or aggregate formed by one or moremolecules of a solute, i.e. a compound of the invention or apharmaceutically-acceptable salt thereof, and one or more molecules of asolvent. Such solvates are typically crystalline solids having asubstantially fixed molar ratio of solute and solvent. Representativesolvents include by way of example, water, methanol, ethanol,isopropanol, acetic acid, and the like. When the solvent is water, thesolvate formed is a hydrate.

It will be appreciated that the term “or a pharmaceutically-acceptablesalt or solvate of stereoisomer thereof” is intended to include allpermutations of salts, solvates and stereoisomers, such as a solvate ofa pharmaceutically-acceptable salt of a stereoisomer of a compound offormula (I).

The term “amino-protecting group” means a protecting group suitable forpreventing undesired reactions at an amino nitrogen. Representativeamino-protecting groups include, but are not limited to, formyl; acylgroups, for example alkanoyl groups, such as acetyl; alkoxycarbonylgroups, such as tert-butoxycarbonyl (Boc); arylmethoxycarbonyl groups,such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethoxycarbonyl (Fmoc);arylmethyl groups, such as benzyl (Bn), trityl (Tr), and1,1-di-(4′-methoxyphenyl)methyl; silyl groups, such as trimethylsilyl(TMS) and tert-butyldimethylsilyl (TBDMS); and the like.

General Synthetic Procedures

Compounds of the invention can be prepared from readily availablestarting materials using the following general methods and procedures.Although a particular aspect of the present invention is illustrated inthe schemes below, those skilled in the art will recognize that allaspects of the present invention can be prepared using the methodsdescribed herein or by using other methods, reagents and startingmaterials known to those skilled in the art. It will also be appreciatedthat where typical or preferred process conditions (i.e., reactiontemperatures, times, mole ratios of reactants, solvents, pressures,etc.) are given, other process conditions can also be used unlessotherwise stated. Optimum reaction conditions may vary with theparticular reactants or solvent used, but such conditions can bedetermined by one skilled in the art by routine optimization procedures.

Additionally, as will be apparent to those skilled in the art,conventional protecting groups may be necessary to prevent certainfunctional groups from undergoing undesired reactions. The choice of asuitable protecting group for a particular functional group, as well assuitable conditions for protection and deprotection, are well known inthe art. For example, numerous protecting groups, and their introductionand removal, are described in T. W. Greene and G. M. Wuts, ProtectingGroups in Organic Synthesis, Third Edition, Wiley, New York, 1999, andreferences cited therein.

In one method of synthesis, compounds of formula (I) are prepared byreacting a piperidinylmethyl-piperidinylmethyl intermediate of formula(II):

with a reagent of formula (III):L-X   (III)where L is a leaving group, for example a halo, such as chloro, or anacyloxy, sulfonic ester, or oxysuccinimide, and R¹ and X are defined asin formula (I).

The reaction is typically conducted by contacting intermediate (II) withbetween about 1 and about 1.5 equivalents of intermediate (III) in apolar aprotic diluent, such as dichloromethane, in the presence of atleast one equivalent of an amine base, such asN,N-diisopropylethylamine. Suitable inert diluents for this process andthose described below, also include N,N-dimethylformamide,trichloromethane, 1,1,2,2-tetrachloroethane, tetrahydrofuran, and thelike. Suitable amine bases for the processes of the present inventionalso include triethylamine, pyridine, and the like. The reaction istypically conducted at a temperature in the range of about 0° C. toabout 30° C. for about a quarter hour to about 2 hours, or until thereaction is substantially complete. Exemplary reagents L-X in which L ischloro include methyl chloroformate, phenyl chloroformate, chlorobenzoylchloride, and methanesulfonyl chloride.

In an alternative method of synthesis, compounds of formula (I) in whichX is selected from —C(O)R³, —C(O)C(R⁶R⁷)R⁸, and —C(O)C(HR⁹)OR¹⁰ can beprepared by the amide coupling reaction of an intermediate of formula(II) with a carboxylic acid of formula (IV):

In formula (IV), X′ represents R³, C(R⁶R⁷)R⁸, or C(HR⁹)OR¹⁰, such that—C(O)X′ corresponds to X, as set forth above formula (IV). In the amidecoupling reaction of intermediate (II), between about 1 and about 1.5equivalents of the carboxylic acid (IV) are first contacted with between1 and about 1.5 equivalents of a coupling agent such asO-(7-axabenzotrizol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate (HATU) in a polar aprotic solvent such asdimethylformamide or those discussed above. The acid mixture is thencontacted with intermediate (II) in the presence of between about 2 andabout 4 equivalents of an amine base, for example,N,N-diisopropylethylamine. The reaction is typically conducted at atemperature in the range of about 0° C. to about 30° C. for about aquarter hour to about 2 hours, or until the reaction is substantiallycomplete.

Suitable alternative coupling agents includeN-ethyl-N-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC),1,1′-carbonyldiimidazole (CDI) 1,3 dicyclohexylcarbodiimide (DCC), andbenzotriazol-1-yloxytripyrrolidino-phosphonium hexafluorophosphate(PyBop). The coupling agents may be combined with promoting agents, forexample, 1-hydroxy-7-azabenzotriazole (HOAt), hydroxybenzotriazole(HOBt), or 1,4-diazabicyclo[2,2,2]octane (DABCO).

In yet another alternative process, compounds of formula (I) in which Xis —C(O)NHR⁵ can be prepared by reacting an intermediate of formula (II)with an isocyanate of the form:O═C═N—R⁵   (V)The reaction is typically conducted by contacting intermediate (II) withbetween about 1 and about 1.5 equivalents of intermediate (V) in a polaraprotic diluent in the presence of at between about 2 and about 4equivalents of an amine base. The reaction is typically conducted at atemperature in the range of about 0° C. to about 30° C. for about aquarter hour to about 24 hours, or until the reaction is substantiallycomplete.

The product of formula (I) is isolated and purified by conventionalprocedures. For example, the product can be concentrated to drynessunder reduced pressure and the residue purified by HPLC chromatography.

The piperidinylmethyl-piperidinylmethyl intermediates of formula (II)are prepared from readily available starting materials by the procedureillustrated in Scheme A.

where P¹ and P² independently represent an amino protecting group, suchas tert-butoxycarbonyl (Boc).

First, a carboxylic acid of formula (VI) is reacted with a protectedaminomethyl piperidine to form a protected intermediate of formula(VII). This reaction is typically conducted by contacting (VI) withbetween about 1 and about 2 equivalents of protectedaminomethylpiperidine in a polar aprotic diluent, in the presence of anamide coupling agent described above, for exampleN-ethyl-N-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC)combined with hydroxybenzotriazole (HOBt) or 1,1′-carbonyldiimidazole(CDI) combined with 1,4-diazabicyclo[2,2,2]octane (DABCO).

The reaction is typically conducted at a temperature in the range ofabout 0° C. to about 60° C. for between about 1 and about 24 hours oruntil the reaction is substantially complete.

The protecting group P¹ is removed from intermediate (VII) byconventional means to provide intermediate (VIII). For example, when Bocis used as the protecting group, it may be removed by treatment with anacid, such as trifluoroacetic acid or hydrochloric acid.

An intermediate of formula (IX) is then formed by the reductiveamination of intermediate (VIII) with a protectedpiperidine-carboxaldehyde. This reaction is typically conducted bycontacting (VIII) with between about 1 and about 2 equivalents of theprotected piperidine-carboxaldehyde in an inert diluent in the presenceof between about 1 and about 2 equivalents of a reducing agent.Optionally, about one equivalent of a weak acid, such as acetic acid canbe included to accelerate the reaction. The reaction may be conducted ata temperature between about 0° C. and about 30° C., typically betweenabout 20° C. and about 30° C., for about 0.25 to about 2 hours, or untilthe reaction is substantially complete.

Suitable inert diluents include dichloromethane, trichloromethane,1,1,2,2-tetrachloroethane, and the like. Typical reducing agents includesodium triacetoxyborohydride, sodium borohydride, and sodiumcyanoborohydride. The product (IX) is isolated by standard procedures.When the amine (VIII) is supplied as an acid salt, typically betweenabout 1 and about 3 equivalents of an amine base, such asN,N-diisopropylethylamine, is included in the reaction. Finally, theprotecting group P² is removed from intermediate (IX) by conventionalprocedures to provide the piperidinylmethyl-piperidinylmethylintermediate (II).

A carboxylic acid of formula (VI) can be prepared from a diaminobenzoicacid or ester by the process illustrated in Scheme B:

where R represents methyl or hydrogen. Intermediate (XI) is reacted witha carboxylic acid R¹C(O)OH to form the acid intermediate (VI). Thisreaction is typically conducted by contacting the acid or ester (XI)with between about 2 and about 4 equivalents of the carboxylic acidR¹C(O)OH in an aqueous acidic solution. The reaction is typicallyconducted at a temperature in the range of about 80° C. to about 100° C.for about 12 to about 72 hours. The pH of the solution is then raised bythe addition of base, such as sodium hydroxide, and the product isolatedby conventional means.

A convenient process for providing intermediate (XI) as the methyl esteruses 2-amino-3-nitrobenzoic acid methyl ester (X):

as the starting material. Typically, 2-amino-3-nitrobenzoic acid methylester (X) is dissolved in a polar diluent and reduced by exposure to ahydrogen atmosphere in the presence of a transition metal catalyst toprovide the diaminobenzoic acid methyl ester (XI). The reaction istypically conducted at ambient temperature for about 12 to about 72hours.

When the substituent R¹ is sterically bulky, as for example, when R¹ istert-butyl, tert-butylbenzimidazole carboxylic acid (VI′) can beprepared by the conversion of methyl ester (XI′) according to a two-stepprocess, as illustrated, for example, in Scheme C:

As described in detail in Preparation 3 below, the methyl ester (XI′) isfirst reacted with 2,2-dimethylpropionyl chloride to provide theintermediate (XII) which is refluxed in a strong acid solution,typically, for between about 12 and about 72 hours, to provide thetert-butylbenzimidazole carboxylic acid (VI′).

In alternative methods of synthesis, compounds of formula (I) can beprepared according to the process routes illustrated in Scheme D usingthe reductive amination and other reactions described above, and/orusing alternative reactions well known to those skilled in the art.

As shown in process route (i), an intermediate of formula (VIII) isreacted with an intermediate of formula (XIII) to provide a compound offormula (I). The reaction is typically performed under the conditionsdescribed above for the reaction of amine (VIII) with the protectedpiperidine-carboxaldehyde in Scheme A.

Intermediate (XIII) can be prepared by the reaction of4-hydroxymethylpiperidine with a reagent L-X, of formula (III), followedby oxidation of the resulting intermediate. For example, for theparticular case of X is —C(O)OCH₃, intermediate (XIII) can be preparedas shown in Scheme E.

First 4-hydroxymethylpiperidine is reacted with methylchloroformate toform the hydroxymethylpiperidine intermediate (XV). The reaction istypically conducted by contacting 4-hydroxymethylpiperidine in anaqueous solution with between about 3 and about 5 equivalents ofmethylchloroformate in the presence of between about 3 and about 5equivalents of base. The reaction is typically conducted at atemperature in the range of about 0° C. to about 30° C. for about 12 toabout 72 hours or until the reaction is substantially complete.Intermediate (XV) is then oxidized to form the formylpiperidinylintermediate (XIII′). The oxidation reaction typically makes use of anoxidation reagent such as a combination of oxalyl chloride anddimethylsulfoxide (Swern oxidation), a chromate reagent, such aspyridinium chlorochromate, or an oxidizing agent, such as sodiumhypochlorite, together with a catalyst such as2,2,6,6-tetramethyl-1-piperidinyloxy free radical (TEMPO).

The preparation of a compound of formula (I) according to process route(i) of Scheme D using intermediate (XIII′) is described in Examples 214and 216 below.

A compound of formula (I) can also be prepared by reacting a carboxylicacid of formula (VI) with an intermediate of formula (XIV), as shown inprocess route (ii). As illustrated in Scheme F, intermediate (XIV) canbe prepared by the reaction of a protected aminomethylpiperidine withintermediate (XIII):

where P is an amino-protecting group, to provide a protectedintermediate of formula (XVI), followed by a deprotection step. Thepreparation of compounds according to process route (ii) is described inPreparation 4 and in Examples 14 and 15 below.

The reagents L-X (III), X′C(O)OH (IV), O═C═N═R⁵ (V) and R¹C(O)OH areavailable commercially or are readily prepared by standard proceduresfrom common starting materials.

Further details regarding specific reaction conditions and otherprocedures for preparing representative compounds of the invention orintermediates thereto are described in the examples below.

Accordingly, in a method aspect, the invention provides a process forpreparing a compound of formula (I), or a salt or stereoisomer thereof,the process comprising (a) reacting a compound of formula (II) withcompound of the formula (III); (b) reacting a compound formula (VIII)with a compound of formula (XIII); or (c) reacting a compound of formula(VI) with a compound of formula (XIV) to provide a compound of formula(I), or a salt or stereoisomer thereof.

In an additional method aspect, the invention provides a process forpreparing a compound of formula (I) wherein X is selected from —C(O)R³,—C(O)C(R⁶R⁷)R⁸, and —C(O)C(HR⁹)OR¹⁰, or a salt or stereoisomer thereof,the process comprising reacting a compound of formula (II) with acompound of formula (IV), wherein X′ represents R³, C(R⁶R⁷)R⁸, orC(HR⁹)OR¹⁰, to provide a compound of formula (I), or a salt orstereoisomer thereof.

The invention further provides a compound of formula (II), or a salt orstereoisomer or protected derivative thereof, wherein R¹ is defined asin formula (I).

Pharmaceutical Compositions

The benzimidazole-carboxamide compounds of the invention are typicallyadministered to a patient in the form of a pharmaceutical composition.Such pharmaceutical compositions may be administered to the patient byany acceptable route of administration including, but not limited to,oral, rectal, vaginal, nasal, inhaled, topical (including transdermal)and parenteral modes of administration.

Accordingly, in one of its compositions aspects, the invention isdirected to a pharmaceutical composition comprising apharmaceutically-acceptable carrier or excipient and a therapeuticallyeffective amount of a compound of formula (I) or a pharmaceuticallyacceptable salt or solvate thereof. Optionally, such pharmaceuticalcompositions may contain other therapeutic and/or formulating agents ifdesired.

The pharmaceutical compositions of the invention typically contain atherapeutically effective amount of a compound of the present inventionor a pharmaceutically-acceptable salt thereof. Typically, suchpharmaceutical compositions will contain from about 0.1 to about 95% byweight of the active agent; including from about 5 to about 70% byweight; and from about 10 to about 60% by weight of the active agent.

Any conventional carrier or excipient may be used in the pharmaceuticalcompositions of the invention. The choice of a particular carrier orexcipient, or combinations of carriers or excipients, will depend on themode of administration being used to treat a particular patient or typeof medical condition or disease state. In this regard, the preparationof a suitable pharmaceutical composition for a particular mode ofadministration is well within the scope of those skilled in thepharmaceutical arts. Additionally, the ingredients for such compositionsare commercially-available from, for example, Sigma, P.O. Box 14508, St.Louis, Mo. 63178. By way of further illustration, conventionalformulation techniques are described in Remington: The Science andPractice of Pharmacy, 20^(th) Edition, Lippincott Williams & White,Baltimore, Md. (2000); and H. C. Ansel et al., Pharmaceutical DosageForms and Drug Delivery Systems, 7^(th) Edition, Lippincott Williams &White, Baltimore, Md. (1999).

Representative examples of materials which can serve as pharmaceuticallyacceptable carriers include, but are not limited to, the following: (1)sugars, such as lactose, glucose and sucrose; (2) starches, such as cornstarch and potato starch; (3) cellulose, such as microcrystallinecellulose, and its derivatives, such as sodium carboxymethyl cellulose,ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5)malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter andsuppository waxes; (9) oils, such as peanut oil, cottonseed oil,safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10)glycols, such as propylene glycol; (11) polyols, such as glycerin,sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyloleate and ethyl laurate; (13) agar; (14) buffering agents, such asmagnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16)pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19)ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxiccompatible substances employed in pharmaceutical compositions.

The pharmaceutical compositions of the invention are typically preparedby thoroughly and intimately mixing or blending a compound of theinvention with a pharmaceutically-acceptable carrier and one or moreoptional ingredients. If necessary or desired, the resulting uniformlyblended mixture can then be shaped or loaded into tablets, capsules,pills and the like using conventional procedures and equipment.

The pharmaceutical compositions of the invention are preferably packagedin a unit dosage form. The term “unit dosage form” refers to aphysically discrete unit suitable for dosing a patient, i.e., each unitcontaining a predetermined quantity of active agent calculated toproduce the desired therapeutic effect either alone or in combinationwith one or more additional units. For example, such unit dosage formsmay be capsules, tablets, pills, and the like.

In a preferred embodiment, the pharmaceutical compositions of theinvention are suitable for oral administration. Suitable pharmaceuticalcompositions for oral administration may be in the form of capsules,tablets, pills, lozenges, cachets, dragees, powders, granules; or as asolution or a suspension in an aqueous or non-aqueous liquid; or as anoil-in-water or water-in-oil liquid emulsion; or as an elixir or syrup;and the like; each containing a predetermined amount of a compound ofthe present invention as an active ingredient.

When intended for oral administration in a solid dosage form (i.e., ascapsules, tablets, pills and the like), the pharmaceutical compositionsof the invention will typically comprise a compound of the presentinvention as the active ingredient and one or morepharmaceutically-acceptable carriers, such as sodium citrate ordicalcium phosphate. Optionally or alternatively, such solid dosageforms may also comprise: (1) fillers or extenders, such as starches,microcrystalline cellulose, lactose, sucrose, glucose, mannitol, and/orsilicic acid; (2) binders, such as carboxymethylcellulose, alginates,gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants,such as glycerol; (4) disintegrating agents, such as agar-agar, calciumcarbonate, potato or tapioca starch, alginic acid, certain silicates,and/or sodium carbonate; (5) solution retarding agents, such asparaffin; (6) absorption accelerators, such as quaternary ammoniumcompounds; (7) wetting agents, such as cetyl alcohol and/or glycerolmonostearate; (8) absorbents, such as kaolin and/or bentonite clay; (9)lubricants, such as talc, calcium stearate, magnesium stearate, solidpolyethylene glycols, sodium lauryl sulfate, and/or mixtures thereof;(10) coloring agents; and (11) buffering agents.

Release agents, wetting agents, coating agents, sweetening, flavoringand perfuming agents, preservatives and antioxidants can also be presentin the pharmaceutical compositions of the invention. Examples ofpharmaceutically-acceptable antioxidants include: (1) water-solubleantioxidants, such as ascorbic acid, cysteine hydrochloride, sodiumbisulfate, sodium metabisulfate sodium sulfite and the like; (2)oil-soluble antioxidants, such as ascorbyl palmitate, butylatedhydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propylgallate, alpha-tocopherol, and the like; and (3) metal-chelating agents,such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol,tartaric acid, phosphoric acid, and the like. Coating agents fortablets, capsules, pills and like, include those used for entericcoatings, such as cellulose acetate phthalate (CAP), polyvinyl acetatephthalate (PVAP), hydroxypropyl methylcellulose phthalate, methacrylicacid-methacrylic acid ester copolymers, cellulose acetate trimellitate(CAT), carboxymethyl ethyl cellulose (CMEC), hydroxypropyl methylcellulose acetate succinate (HPMCAS), and the like.

If desired, the pharmaceutical compositions of the present invention mayalso be formulated to provide slow or controlled release of the activeingredient using, by way of example, hydroxypropyl methyl cellulose invarying proportions; or other polymer matrices, liposomes and/ormicrospheres.

In addition, the pharmaceutical compositions of the present inventionmay optionally contain opacifying agents and may be formulated so thatthey release the active ingredient only, or preferentially, in a certainportion of the gastrointestinal tract, optionally, in a delayed manner.Examples of embedding compositions which can be used include polymericsubstances and waxes. The active ingredient can also be inmicro-encapsulated form, if appropriate, with one or more of theabove-described excipients.

Suitable liquid dosage forms for oral administration include, by way ofillustration, pharmaceutically-acceptable emulsions, microemulsions,solutions, suspensions, syrups and elixirs. Such liquid dosage formstypically comprise the active ingredient and an inert diluent, such as,for example, water or other solvents, solubilizing agents andemulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate,ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol,1,3-butylene glycol, oils (esp., cottonseed, groundnut, corn, germ,olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol,polyethylene glycols and fatty acid esters of sorbitan, and mixturesthereof. Suspensions, in addition to the active ingredient, may containsuspending agents such as, for example, ethoxylated isostearyl alcohols,polyoxyethylene sorbitol and sorbitan esters, microcrystallinecellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth,and mixtures thereof.

Alternatively, the pharmaceutical compositions of the invention areformulated for administration by inhalation. Suitable pharmaceuticalcompositions for administration by inhalation will typically be in theform of an aerosol or a powder. Such compositions are generallyadministered using well-known delivery devices, such as a metered-doseinhaler, a dry powder inhaler, a nebulizer or a similar delivery device.

When administered by inhalation using a pressurized container, thepharmaceutical compositions of the invention will typically comprise theactive ingredient and a suitable propellant, such asdichlorodifluoromethane, trichlorofluoromethane,dichlorotetrafluoroethane, carbon dioxide or other suitable gas.

Additionally, the pharmaceutical composition may be in the form of acapsule or cartridge (made, for example, from gelatin) comprising acompound of the invention and a powder suitable for use in a powderinhaler. Suitable powder bases include, by way of example, lactose orstarch.

The compounds of the invention can also be administered transdermallyusing known transdermal delivery systems and excipients. For example, acompound of the invention can be admixed with permeation enhancers, suchas propylene glycol, polyethylene glycol monolaurate,azacycloalkan-2-ones and the like, and incorporated into a patch orsimilar delivery system. Additional excipients including gelling agents,emulsifiers and buffers, may be used in such transdermal compositions ifdesired.

The following formulations illustrate representative pharmaceuticalcompositions of the present invention:

Formulation Example A

Hard gelatin capsules for oral administration are prepared as follows:

Ingredients Amount Compound of the invention  50 mg Lactose(spray-dried) 200 mg Magnesium stearate  10 mg

-   -   Representative Procedure: The ingredients are thoroughly blended        and then loaded into a hard gelatin capsule (260 mg of        composition per capsule).

Formulation Example B

Hard gelatin capsules for oral administration are prepared as follows:

Ingredients Amount Compound of the invention 20 mg Starch 89 mgMicrocrystalline cellulose 89 mg Magnesium stearate  2 mg

-   -   Representative Procedure: The ingredients are thoroughly blended        and then passed through a No. 45 mesh U.S. sieve and loaded into        a hard gelatin capsule (200 mg of composition per capsule).

Formulation Example C

Capsules for oral administration are prepared as follows:

Ingredients Amount Compound of the invention  10 mg Polyoxyethylenesorbitan monooleate  50 mg Starch powder 250 mg

-   -   Representative Procedure: The ingredients are thoroughly blended        and then loaded into a gelatin capsule (310 mg of composition        per capsule).

Formulation Example D

Tablets for oral administration are prepared as follows:

Ingredients Amount Compound of the invention   5 mg Starch  50 mgMicrocrystalline cellulose  35 mg Polyvinylpyrrolidone (10 wt. % inwater)   4 mg Sodium carboxymethyl starch 4.5 mg Magnesium stearate 0.5mg Talc   1 mg

-   -   Representative Procedure: The active ingredient, starch and        cellulose are passed through a No. 45 mesh U.S. sieve and mixed        thoroughly. The solution of polyvinylpyrrolidone is mixed with        the resulting powders, and this mixture is then passed through a        No. 14 mesh U.S. sieve. The granules so produced are dried at        50-60° C. and passed through a No. 18 mesh U.S. sieve. The        sodium carboxymethyl starch, magnesium stearate and talc        (previously passed through a No. 60 mesh U.S. sieve) are then        added to the granules. After mixing, the mixture is compressed        on a tablet machine to afford a tablet weighing 100 mg.

Formulation Example E

Tablets for oral administration are prepared as follows:

Ingredients Amount Compound of the invention  25 mg Microcrystallinecellulose 400 mg Silicon dioxide fumed  10 mg Stearic acid   5 mg

-   -   Representative Procedure: The ingredients are thoroughly blended        and then compressed to form tablets (440 mg of composition per        tablet).

Formulation Example F

Single-scored tablets for oral administration are prepared as follows:

Ingredients Amount Compound of the invention  15 mg Cornstarch  50 mgCroscarmellose sodium  25 mg Lactose 120 mg Magnesium stearate  5 mg

-   -   Representative Procedure: The ingredients are thoroughly blended        and compressed to form a single-scored tablet (215 mg of        compositions per tablet).

Formulation Example G

A suspension for oral administration is prepared as follows:

Ingredients Amount Compound of the invention   0.1 g Fumaric acid   0.5g Sodium chloride   2.0 g Methyl paraben  0.15 g Propyl paraben  0.05 gGranulated sugar  25.5 g Sorbitol (70% solution) 12.85 g Veegum k(Vanderbilt Co.)  1.0 g Flavoring 0.035 mL Colorings  0.5 mg Distilledwater q.s. to 100 mL

-   -   Representative Procedure: The ingredients are mixed to form a        suspension containing 10 mg of active ingredient per 10 mL of        suspension.

Formulation Example H

A dry powder for administration by inhalation is prepared as follows:

Ingredients Amount Compound of the invention 1.0 mg Lactose  25 mg

-   -   Representative Procedure: The active ingredient is micronized        and then blended with lactose. This blended mixture is then        loaded into a gelatin inhalation cartridge. The contents of the        cartridge are administered using a powder inhaler.

Formulation Example I

A dry powder for administration by inhalation in a metered dose inhaleris prepared as follows:

-   -   Representative Procedure: A suspension containing 5 wt. % of a        compound of the invention and 0.1 wt. % lecithin is prepared by        dispersing 10 g of active compound as micronized particles with        mean size less than 10 μm in a solution formed from 0.2 g of        lecithin dissolved in 200 mL of demineralized water. The        suspension is spray dried and the resulting material is        micronized to particles having a mean diameter less than 1.5 The        particles are loaded into cartridges with pressurized        1,1,1,2-tetrafluoroethane.

Formulation Example J

An injectable formulation is prepared as follows:

Ingredients Amount Compound of the invention 0.2 g Sodium acetate buffersolution (0.4M)  40 mL HCl (0.5N) or NaOH (0.5N) q.s. to pH 4 Water(distilled, sterile) q.s. to 20 mL

-   -   Representative Procedure: The above ingredients are blended and        the pH is adjusted to 4±0.5 using 0.5 N HCl or 0.5 N NaOH.

Formulation Example K

Capsules for oral administration are prepared as follows:

Ingredients Amount Compound of the Invention 4.05 mg Microcrystallinecellulose (Avicel PH 103) 259.2 mg Magnesium stearate 0.75 mg

-   -   Representative Procedure: The ingredients are thoroughly blended        and then loaded into a gelatin capsule (Size #1, White, Opaque)        (264 mg of composition per capsule).

Formulation Example L

Capsules for oral administration are prepared as follows:

Ingredients Amount Compound of the Invention 8.2 mg Microcrystallinecellulose (Avicel PH 103) 139.05 mg Magnesium stearate 0.75 mg

-   -   Representative Procedure: The ingredients are thoroughly blended        and then loaded into a gelatin capsule (Size #1, White, Opaque)        (148 mg of composition per capsule).

It will be understood that any form of the compounds of the invention,(i.e. free base, pharmaceutical salt, or solvate) that is suitable forthe particular mode of administration, can be used in the pharmaceuticalcompositions discussed above.

Utility

The benzimidazole-carboxamide compounds of the invention are 5-HT₄receptor agonists and therefore are expected to be useful for treatingmedical conditions mediated by 5-HT₄ receptors or associated with 5-HT₄receptor activity, i.e. medical conditions which are ameliorated bytreatment with a 5-HT₄ receptor agonist. Such medical conditionsinclude, but are not limited to, irritable bowel syndrome (IBS), chronicconstipation, functional dyspepsia, delayed gastric emptying,gastroesophageal reflux disease (GERD), gastroparesis, post-operativeileus, intestinal pseudo-obstruction, and drug-induced delayed transit.In addition, it has been suggested that some 5-HT₄ receptor agonistcompounds may be used in the treatment of central nervous systemdisorders including cognitive disorders, behavioral disorders, mooddisorders, and disorders of control of autonomic function.

In particular, the compounds of the invention increase motility of thegastrointestinal (GI) tract and thus are expected to be useful fortreating disorders of the GI tract caused by reduced motility inmammals, including humans. Such GI motility disorders include, by way ofillustration, chronic constipation, constipation-predominant irritablebowel syndrome (C-IBS), diabetic and idiopathic gastroparesis, andfunctional dyspepsia.

In one aspect, therefore, the invention provides a method of increasingmotility of the gastrointestinal tract in a mammal, the methodcomprising administering to the mammal a therapeutically effectiveamount of a pharmaceutical composition comprising apharmaceutically-acceptable carrier and a compound of the invention.

When used to treat disorders of reduced motility of the GI tract orother conditions mediated by 5-HT₄ receptors, the compounds of theinvention will typically be administered orally in a single daily doseor in multiple doses per day, although other forms of administration maybe used. The amount of active agent administered per dose or the totalamount administered per day will typically be determined by a physician,in the light of the relevant circumstances, including the condition tobe treated, the chosen route of administration, the actual compoundadministered and its relative activity, the age, weight, and response ofthe individual patient, the severity of the patient's symptoms, and thelike.

Suitable doses for treating disorders of reduced motility of the GItract or other disorders mediated by 5-HT₄ receptors will range fromabout 0.0007 to about 20 mg/kg/day of active agent, including from about0.0007 to about 1 mg/kg/day. For an average 70 kg human, this wouldamount to from about 0.05 to about 70 mg per day of active agent.

In one aspect of the invention, the compounds of the invention are usedto treat chronic constipation. When used to treat chronic constipation,the compounds of the invention will typically be administered orally ina single daily dose or in multiple doses per day. Preferably, the dosefor treating chronic constipation will range from about 0.05 to about 70mg per day.

In another aspect of the invention, the compounds of the invention areused to treat irritable bowel syndrome. When used to treatconstipation-predominant irritable bowel syndrome, the compounds of theinvention will typically be administered orally in a single daily doseor in multiple doses per day. Preferably, the dose for treatingconstipation-predominant irritable bowel syndrome will range from about0.05 to about 70 mg per day.

In another aspect of the invention, the compounds of the invention areused to treat diabetic gastroparesis. When used to treat diabeticgastroparesis, the compounds of the invention will typically beadministered orally in a single daily dose or in multiple doses per day.Preferably, the dose for treating diabetic gastroparesis will range fromabout 0.05 to about 70 mg per day.

In yet another aspect of the invention, the compounds of the inventionare used to treat functional dyspepsia. When used to treat functionaldyspepsia, the compounds of the invention will typically be administeredorally in a single daily dose or in multiple doses per day. Preferably,the dose for treating functional dyspepsia will range from about 0.05 toabout 70 mg per day.

The invention also provides a method of treating a mammal having adisease or condition associated with 5-HT₄ receptor activity, the methodcomprising administering to the mammal a therapeutically effectiveamount of a compound of the invention or of a pharmaceutical compositioncomprising a compound of the invention.

As described above, compounds of the invention are 5-HT₄ receptoragonists. The invention further provides, therefore, a method ofagonizing a 5-HT₄ receptor in a mammal, the method comprisingadministering a compound of the invention to the mammal. In addition,the compounds of the invention are also useful as research tools forinvestigating or studying biological systems or samples having 5-HT₄receptors, or for discovering new 5-HT₄ receptor agonists. Moreover,since compounds of the invention exhibit binding selectivity for 5-HT₄receptors as compared with binding to receptors of other 5-HT subtypes,particularly 5-HT₃ receptors, such compounds are particularly useful forstudying the effects of selective agonism of 5-HT₄ receptors in abiological system or sample. Any suitable biological system or samplehaving 5-HT₄ receptors may be employed in such studies which may beconducted either in vitro or in vivo. Representative biological systemsor samples suitable for such studies include, but are not limited to,cells, cellular extracts, plasma membranes, tissue samples, mammals(such as mice, rats, guinea pigs, rabbits, dogs, pigs, etc.) and thelike.

In this aspect of the invention, a biological system or samplecomprising a 5-HT₄ receptor is contacted with a 5-HT₄ receptor-agonizingamount of a compound of the invention. The effects of agonizing the5-HT₄ receptor are then determined using conventional procedures andequipment, such as radioligand binding assays and functional assays.Such functional assays include ligand-mediated changes in intracellularcyclic adenosine monophosphate (cAMP), ligand-mediated changes inactivity of the enzyme adenylyl cyclase (which synthesizes cAMP),ligand-mediated changes in incorporation of analogs of guanosinetriphosphate (GTP), such as [³⁵S]GTPγS (guanosine5′-O-(γ-thio)triphosphate) or GTP-Eu, into isolated membranes viareceptor catalyzed exchange of GTP analogs for GDP analogs,ligand-mediated changes in free intracellular calcium ions (measured,for example, with a fluorescence-linked imaging plate reader or FLIPR®from Molecular Devices, Inc.), and measurement of mitogen activatedprotein kinase (MAPK) activation. A compound of the invention mayagonize or increase the activation of 5-HT₄ receptors in any of thefunctional assays listed above, or assays of a similar nature. A 5-HT₄receptor-agonizing amount of a compound of the invention will typicallyrange from about 1 nanomolar to about 500 nanomolar.

Additionally, the compounds of the invention can be used as researchtools for discovering new 5-HT₄ receptor agonists. In this embodiment,5-HT₄ receptor binding or functional data for a test compound or a groupof test compounds is compared to the 5-HT₄ receptor binding orfunctional data for a compound of the invention to identify testcompounds that have superior binding or functional activity, if any.This aspect of the invention includes, as separate embodiments, both thegeneration of comparison data (using the appropriate assays) and theanalysis of the test data to identify test compounds of interest.

Among other properties, compounds of the invention have been found to bepotent agonists of the 5-HT₄ receptor and to exhibit substantialselectivity for the 5-HT₄ receptor subtype over the 5-HT₃ receptorsubtype in radioligand binding assays. Further, compounds of theinvention of which particular mention was made have demonstratedsuperior pharmacokinetic properties in a rat model. Such compounds arethus expected to be highly bioavailable upon oral administration. Inaddition, these compounds have been shown not to exhibit an unacceptablelevel of inhibition of the potassium ion current in an in vitrovoltage-clamp model using isolated whole cells expressing the hERGcardiac potassium channel. The voltage-clamp assay is an acceptedpre-clinical method of assessing the potential for pharmaceutical agentsto change the pattern of cardiac repolarization, specifically to cause,so-called QT prolongation, which has been associated with cardiacarrhythmia. (Cavero et al., Opinion on Pharmacotherapy, 2000, 1, 947-73,Fermini et al., Nature Reviews Drug Discovery, 2003, 2, 439-447)Accordingly, pharmaceutical compositions comprising compounds of theinvention are expected to have an acceptable cardiac profile.

There properties, as well as the utility of the compounds of theinvention, can be demonstrated using various in vitro and in vivo assayswell-known to those skilled in the art. Representative assays aredescribed in further detail in the following examples.

EXAMPLES

The following synthetic and biological examples are offered toillustrate the invention, and are not to be construed in any way aslimiting the scope of the invention. In the examples below, thefollowing abbreviations have the following meanings unless otherwiseindicated. Abbreviations not defined below have their generally acceptedmeanings.

Boc=tert-butoxycarbonyl

DMSO=dimethyl sulfoxide

MeCN=acetonitrile

TFA=trifluoroacetic acid

R_(f) retention factor

Reagents and solvents were purchased from commercial suppliers (Aldrich,Fluka, Sigma, etc.), and used without further purification. Reactionswere run under nitrogen atmosphere, unless noted otherwise. Progress ofreaction mixtures was monitored by thin layer chromatography (TLC),analytical high performance liquid chromatography (anal. HPLC), and massspectrometry, the details of which are given below and separately inspecific examples of reactions. Reaction mixtures were worked up asdescribed specifically in each reaction; commonly they were purified byextraction and other purification methods such as temperature-, andsolvent-dependent crystallization, and precipitation. In addition,reaction mixtures were routinely purified by preparative HPLC: a generalprotocol is described below. Characterization of reaction products wasroutinely carried out by mass and ¹H-NMR spectrometry. For NMRmeasurement, samples were dissolved in deuterated solvent (CD₃OD, CDCl₃,or DMSO-d₆), and ¹H-NMR spectra were acquired with a Varian Gemini 2000instrument (300 MHz) under standard observation conditions. Massspectrometric identification of compounds was performed by anelectrospray ionization method (ESMS) with an Applied Biosystems (FosterCity, Calif.) model API 150 EX instrument or an Agilent (Palo Alto,Calif.) model 1100 LC/MSD instrument.

Preparation 1: Synthesis of 2-isopropyl-1H-benzoimidazole-4-carboxylicAcid (piperidin-4-ylmethyl)amide

a. Preparation of 2,3-diaminobenzoic Acid Methyl Ester

To a nitrogen-saturated solution of 2-amino-3-nitrobenzoic acid methylester (Chess GmbH, 50 g, 0.26 mol) in absolute ethanol (800 mL) wasadded palladium hydroxide (Degussa, 20% w/w on carbon, 58.75% w/w water,10 g). The slurry was degassed then shaken vigorously under hydrogen (4atm) at room temperature for 48 h. The catalyst was filtered and thefiltrate concentrated in vacuo to afford 2,3-diaminobenzoic acid methylester as a dark orange oil that solidified on standing (43 g, 0.26 mol,100%). (m/z): [M+OCH₃]⁺ calcd for C₈H₁₀N₂O₂, 135.05; found 135.3. ¹H NMR(300 MHz, DMSO-d₆): δ (ppm) 3.74 (s, 3H), 4.80 (br s, 1H), 6.20 (br s,1H), 6.38 (t, 1H), 6.70 (d, 1H), 7.06 (d, 1H).

b. Preparation of 2-isopropyl-1H-benzoimidazole-4-carboxylic Acid

A slurry of 2,3-diaminobenzoic acid methyl ester (21.5 g, 0.13 mol) andisobutyric acid (36.2 mL, 0.39 mol) in aqueous hydrochloric acid (4M,210 mL) was stirred under reflux for 24 h to afford a homogenoussolution. The solution was cooled to 10° C. and the pH raised to 3.5using aqueous sodium hydroxide solution (4M, approx. 210 mL), whilemaintaining the temperature below 30° C. The reaction mixture wasstirred at room temperature for 2 h, cooled to 10° C., and the resultantprecipitate filtered off. The solid cake was transferred to a beaker andacetonitrile (300 mL) was added. The slurry was stirred at roomtemperature for 1 h then and filtered to afford a grey solid. The solidwas dried under vacuum to afford the title intermediate (23 g, 0.11 mol,87%). (m/z): [M+H]⁺ calcd for C₁₁H₁₂N₂O₂, calcd. 205.09; found 205.3. ¹HNMR (300 MHz, DMSO-d₆): δ (ppm) 1.27 (d, 6H), 3.39 (m, 1H), 7.29 (t,1H), 7.78 (m, 2H).

c. Preparation of4-{[(2-isopropyl-1H-benzoimidazole-4-carbonyl)amino]methyl}-piperidine-1-carboxylicAcid Tert-Butyl Ester

To a solution of 2-isopropyl-1H-benzoimidazole-4-carboxylic acid (9.0 g,44.1 mmol) in anhydrous N,N-dimethylformamide (100 mL) was added4-aminomethyl-piperidine-1-carboxylic acid tert-butyl ester (9.4 g, 44.1mmol), followed by N,N-diisopropylethylamine (16.9 mL, 97.0 mmol). Thesolution was stirred for 15 min at room temperature prior to theaddition of hydroxybenzotriazole (5.9 g, 44.1 mmol),N-Ethyl-N-(3-dimethylaminopropyl)carbodiimide hydrochloride (8.4 g, 44.1mmol), and additional N,N-dimethylformamide (50 mL). The reactionmixture was stirred at room temperature for 16 h, diluted withdichloromethane (300 mL), and washed sequentially with 1M aqueousphosphoric acid, 1M aqueous sodium hydroxide and brine. The solution wasthen dried over sodium sulfate and concentrated in vacuo to afford abrown oil which solidified upon addition of hexanes. The solid wasfiltered to give the title intermediate as a beige solid (13.8 g, 36.0mmol, 78%). (m/z): [M+H]⁺ calcd for C₂₂H₃₂N₄O₃, 401.26; found 401.5;[M-Boc+H]⁺ 301.5. Retention time (anal. HPLC: 2-90% MeCN/H₂O over 6min)=3.7 min. ¹H NMR (300 MHz, DMSO-d₆): δ (ppm) 1.20 (m, 2H), 1.37 (s,9H), 1.37 (s, 6H), 1.72 (m, 1H), 1.75 (m, 2H), 2.73 (br s, 2H), 3.22(septet, 1H), 3.36 (m, 2H), 3.95 (m, 2H), 7.26 (t, 1H), 7.63 (d, 1H),7.79 (d, 1H), 10.11 (t, 1H).

d. Synthesis of 2-isopropyl-1H-benzoimidazole-4-carboxylic acid(piperidin-4-ylmethyl)amide

To a solution of4-{[(2-isopropyl-1H-benzoimidazole-4-carbonyl)amino]methyl}-piperidine-1-carboxylicacid tert-butyl ester (10.8 g, 27.0 mmol) dissolved in dichloromethane(50 mL) at 0° C. was slowly added trifluoroacetic acid (50 mL) in 5 mLportions. The solution was allowed to warm to room temperature, stirredfor an additional 20 minutes then evaporated in vacuo. Excesstrifluoroacetic acid was removed by co-evaporation with toluene. Theresidue was then dissolved in a minimal volume of dichloromethane andslowly added to diethyl ether (1 L) at 0° C. The resulting slurry wasstirred for 2 h at room temperature then filtered to afford thebis-trifluoroacetate salt of the title compound as a light brown solid(12.7 g, 24.0 mmol, 89%). (m/z): [M+H]⁺ calcd for C₁₇H₂₄N₄O, 301.21;found 301.5. Retention time (anal. HPLC: 2-50% MeCN/H₂O over 6 min)=1.65min. ¹H NMR (300 MHz, MeOD-d₃): δ (ppm) 1.59 (d, 6H), 1.60 (m, 1H), 2.03(m, 2H), 2.04 (m, 1H), 3.00 (m, 2H), 3.43 (m, 2H), 3.45 (m, 2H), 3.63(septet, 1H), 7.63 (t, 1H), 7.90 (d, 1H), 7.96 (d, 1H), 9.04 (t, 1H).

Preparation 2: Synthesis of 2-isopropyl-1H-benzoimidazole-4-carboxylicacid (1-piperidin-4-ylmethylpiperidin-4-ylmethyl)amide

a. Preparation of4-(4-{[(2-isopropyl-1H-benzoimidazole-4-carbonyl)amino]methyl}-piperidin-1-ylmethyl)piperidine-1-carboxylicAcid Tert-Butyl Ester

To a suspension of 2-isopropyl-1H-benzoimidazole-4-carboxylic acid(piperidin-4-ylmethyl)amide bis-trifluoroacetate (6.84 g, 12.95 mmol) indichloromethane (65 mL) at room temperature under nitrogen was addedsequentially N,N-diisopropylethylamine (1.67 g, 2.25 mL), a solution of1-(tert-butoxycarbonyl)piperidine-4-carboxaldehyde (3.16 g, 14.89 mmol)in dichloromethane (5 mL) and sodium triacetoxyborohydride (3.84 g,18.13 mmol). The resulting mixture was stirred at room temperature for1.5 h, then acidified to pH 1 with 1M aqueous hydrochloric acid. Theaqueous layer was removed, and the organic layer extracted with 1Maqueous hydrochloric acid until no product remained in the organicphase. The combined aqueous layers were washed with dichloromethane,cooled to 0° C. and basified to pH 12 with sodium hydroxide pellets. Thesolution was then extracted with dichloromethane until no productremained in the aqueous phase, and the combined organic layers washedwith brine, dried over sodium sulfate, filtered and concentrated to givethe desired product as a brown oil (5.4 g, 10.8 mmol, 84%) which wasused without further purification. (m/z): [M+H]⁺ calcd for C₂₈H₄₃N₅O₃,498.35; found 498.5.

b. Synthesis of 2-isopropyl-1H-benzoimidazole-4-carboxylic acid(1-piperidin-4-ylmethylpiperidin-4-ylmethyl)amide

The product of the previous step (5.4 g, 10.8 mmol) was dissolved indichloromethane (40 mL) and cooled to 0° C. Trifluoroacetic acid (30 mL)was added, and the solution was stirred at 0° C. for a further 0.5 h.The mixture was then concentrated and co-evaporated twice withdichloromethane in vacuo. The resulting residue was dissolved indichloromethane (20 mL), cooled to 0° C. and basified with 20% w/waqueous sodium hydroxide (50 mL). The solution was allowed to warm toroom temperature over 10 minutes, then filtered. The solid was rinsedwith acetonitrile and dried in vacuo to afford a light gray powder (3.09g, 7.8 mmol, 72%) which was used without further purification. (m/z):[M+H]⁺ calcd for C₂₃H₃₅N₅O, 398.29; found 398.4.

Preparation 3: Synthesis of 2-tert-butyl-1H-benzoimidazole-4-carboxylicacid (1-piperidin-4-ylmethylpiperidin-4-ylmethyl)amide

a. Preparation of 2-amino-3-(2,2-dimethylpropionylamino)benzoic AcidMethyl Ester

To a solution of 2,3-diaminobenzoic acid methyl ester (2.3 g, 13.8 mmol)in pyridine (40 mL) at room temperature was added 2,2-dimethylpropionylchloride (1.7 g, 14.0 mmol). The solution was stirred at for 16 h,evaporated, and the residue partitioned between ethyl acetate (100 mL)and 1M aqueous hydrochloric acid (100 mL). The organic phase wasseparated, washed with 1M aqueous hydrochloric acid (100 mL), dried oversodium sulfate and evaporated to afford the title compound as a dark oil(2.7 g, 10.8 mmol, 78%) which was used without further purification.(m/z): [M+H]⁺ calcd for C₁₃H₁₈N₂O₃, 251.14; found 250.8

b. Preparation of 2-tert-butyl-1H-benzoimidazole-4-carboxylic Acid

A slurry of the product of the previous step (2.7 g, 10.8 mmol) in 4Maqueous hydrochloric acid (100 mL) was stirred under reflux for 24 h toafford a homogenous solution. The solvent was evaporated to afford thehydrochloride salt of the title intermediate as a brick-red solid (2.5g, 9.8 mmol, 91%). (m/z): [M+H]⁺ calcd for C₁₂H₁₄N₂O₂, 219.12; found219.3. ¹H NMR (300 MHz, DMSO-d₆): δ (ppm) 1.45 (d, 9H), 3.39 (m, 1H),7.91 (d, 1H), 7.95 (d, 1H).

c. Preparation of4-{[(2-tert-butyl-1H-benzoimidazole-4-carbonyl)amino]methyl}-piperidine-1-carboxylicAcid Tert-Butyl Ester

To a solution of 2-tert-butyl-1H-benzoimidazole-4-carboxylic acidhydrochloride (1.11 g, 4.37 mmol) in anhydrous N,N-dimethylformamide (5mL) was added 1,1′-carbonyldiimidazole (0.77 g, 4.75 mmol). The solutionwas stirred at 50° C. for 2 h, then4-aminomethyl-piperidine-1-carboxylic acid tert-butyl ester (0.94 g,4.39 mmol) was added, followed by 1,4-diazabicyclo[2,2,2]octane (1.46 g,13 mmol). The solution was stirred at 50° C. for 16 h, allowed to cooland diluted with water (20 mL) and ethyl acetate (60 mL). The aqueouslayer was removed, the organic layer washed with water (20 mL), driedover sodium sulfate and concentrated in vacuo to afford the titleintermediate (1.32 g, 3.18 mmol, 73%) which was used without furtherpurification. (m/z): [M+H]⁺ calcd for C₂₃H₃₄N₄O₃, 415.27; found 415.5.

d. Preparation of 2-tert-butyl-1H-benzoimidazole-4-carboxylic acid(piperidin-4-ylmethyl)amide

4-{[(2-tert-Butyl-1H-benzoimidazole-4-carbonyl)amino]methyl}-piperidine-1-carboxylicacid tert-butyl ester (13.5 g, 32.6 mmol) was dissolved in 4N HCl indioxane (200 mL) and stirred at room temperature for 0.5 h. Theresulting solid was filtered to afford the bis hydrochloride salt of thetitle intermediate (11.3 g, 29.3 mmol, 89%). (m/z): [M+H]⁺ calcd forC₁₈H₂₆N₄O, 315.22; found 315.3. ¹H NMR (300 MHz, D₂O+MeOD-d₃): 1.54 (s,8H), 1.96 (m, 4H), 2.91 (m, 4H), 3.31 (br s, 1H), 3.45 (d, 2H), 7.56 (t,1H), 7.89-7.92 (m, 2H)

e. Preparation of4-(4-{[(2-tert-butyl-1H-benzoimidazole-4-carbonyl)amino]methyl}-piperidin-1-ylmethyl)piperidine-1-carboxylicAcid Tert-Butyl Ester

To a suspension of the bis HCl salt of2-tert-butyl-1H-benzoimidazole-4-carboxylic acid(piperidin-4-ylmethyl)amide (4.28 g, 11.06 mmol) in dichloromethane (55mL) at room temperature was added N,N-diisopropylethylamine (1.71 g,2.31 mL), 1-(tert-butoxycarbonyl)piperidine-4-carboxaldehyde (2.58 g,12.17 mmol) and sodium triacetoxyborohydride (3.28 g, 15.48 mmol)sequentially. The resulting mixture was stirred at room temperature for2 h then extracted with 1M aqueous hydrochloric acid. The combinedaqueous layers were basified to pH 12 with sodium hydroxide pellets,then extracted with dichloromethane. The combined organic layers weredried over sodium sulfate, filtered and evaporated. The resultingresidue was dried under high vacuum to give a light brownish foam (4.9g, 9.6 mmol, 87%) which was used without further purification. (m/z):[M+H]⁺ calcd for C₂₉H₄₅N₅O₃, 512.35, found: 512.4.

f. Synthesis of 2-tert-butyl-1H-benzoimidazole-4-carboxylic acid(1-piperidin-4-ylmethylpiperidin-4-ylmethyl)amide

Crude4-(4-{[(2-tert-butyl-1H-benzoimidazole-4-carbonyl)amino]methyl}-piperidin-1-ylmethyl)piperidine-1-carboxylicacid tert-butyl ester, prepared as in the previous step (5.1 g, 10 mmol)was treated with a mixture of trifluoroacetic acid (40 mL) anddichloromethane (40 mL) at room temperature for 0.5 h. The mixture wasconcentrated in vacuo, redissolved in dichloromethane (25 mL) andbasified with 1M aqueous sodium hydroxide (15 mL). The organic layer wasremoved, and the aqueous layer re-extracted with dichloromethane. Thecombined organic phases were dried over sodium sulfate, filtered, andconcentrated in vacuo to afford the desired product as a brown foam (3.6g, 8.8 mmol, 88%). (m/z): [M+H]⁺ calcd for C₂₄H₃₇N₅O, 412.31, found412.6.

Preparation 4. Synthesis of4-(4-aminomethylpiperidin-1-ylmethyl)-piperidine-1-carboxylic AcidMethyl Ester

a. Preparation of4-[4-(tert-butoxycarbonylamino-methyl)piperidin-1-ylmethyl]-piperidine-1-carboxylicAcid Methyl Ester

To a solution of 4-tert-butoxycarbonylaminomethylpiperidine (3.62 g,16.9 mmol) in dichloromethane (100 mL) was added4-formylpiperidine-1-carboxylic acid methyl ester (2.89 g, 16.9 mmol)and acetic acid (0.96 mL). The mixture was stirred at room temperaturefor 10 min prior to the addition of sodium triacetoxyborohydride (5.4 g,25.5 mmol). The final mixture was stirred at room temperature for 1 h.The reaction was terminated by adding saturated sodium bicarbonatesolution (50 mL). The mixture was extracted with dichloromethane (100mL), and the organic layer was dried over MgSO₄. Evaporation of theorganic solution afforded a pale yellow oily residue. It was purified byflash silica column chromatography (CH₂Cl₂ to 5% MeOH/CH₂Cl₂), yieldingthe title intermediate (4.4 g). (m/z): [M+H]⁺ calcd for C₁₉H₃₅N₃O₄,370.27; found 370.5.

b. Synthesis of4-(4-aminomethylpiperidin-1-ylmethyl)-piperidine-1-carboxylic AcidMethyl Ester

To a solution of4-[4-(tert-butoxycarbonylamino-methyl)piperidin-1-ylmethyl]-piperidine-1-carboxylicacid methyl ester (4.4 g, 10.8 mmol) in dichloromethane (20 mL) wasadded trifluoroacetic acid (20 mL). After stirring for 20 min at roomtemperature, the solution was evaporated in vacuo, yielding thebis-trifluoroacetate salt of the title compound as a pale yellow oil,which was used without further treatment. (m/z): [M+H]⁺ calcd forC₁₄H₂₇N₃O₂, 270.22; found 270.5. ¹H-NMR (CD₃OD) δ (ppm) 4.0 (br d, 2H),3.6 (m, 5H), 2.9-2.7 (m, 6H), 2.1-1.9 (m, 2H), 1.7-1.5 (m, 6H), 1.2-1.0(m, 4H).

Example 1: Synthesis of4-(4-{[(2-isopropyl-1H-benzoimidazole-4-carbonyl)-amino]methyl}piperidin-1-ylmethyl)piperidine-1-carboxylicAcid Methyl Ester

To a suspension of 2-isopropyl-1H-benzoimidazole-4-carboxylic acid(1-piperidin-4-ylmethylpiperidin-4-ylmethyl)amide (2.9 g, 7.3 mmol) indichloromethane (50 mL) was added N,N-diisopropylethylamine (1.05 mL,7.3 mmol). The resulting solution was cooled to 0° C., and methylchloroformate (576 μL, 7.3 mmol) was added dropwise. The mixture wasstirred at 0° C. for 1.5 h, quenched with acetic acid (1 mL) andevaporated in vacuo to afford a beige solid (4.8 g) which was purifiedvia preparative reverse phase HPLC [gradient of 5-10-25% (5-10% over 10min; 10-25% over 50 min); flow rate 15 mL/min; detection at 280 nm] toafford the bis trifluoroacetate salt of the title compound as a whitesolid (3.5 g, 5.1 mmol, 70%). (m/z): [M+H]⁺ calcd for C₂₅H₃₇N₅O₃,456.30; found 456.3. Retention time (anal. HPLC: 2-50% MeCN/H₂O over 6min)=3.06 min.

Example 2: Synthesis of4-(4-{[(2-isopropyl-1H-benzoimidazole-4-carbonyl)-amino]-methyl}piperidin-1-ylmethyl)piperidine-1-carboxylicAcid Phenyl Ester

To a solution of 2-isopropyl-1H-benzoimidazole-4-carboxylic acid(1-piperidin-4-ylmethylpiperidin-4-ylmethyl)amide (0.22 g, 0.55 mmol)and N,N-diisopropylethylamine (0.19 mL) in dichloromethane (5.0 mL) wasadded phenyl chloroformate (70 μL). The mixture was stirred at roomtemperature for 10 min, then concentrated in vacuo and purified viapreparative reverse phase HPLC to afford the bis trifluoroacetate saltof the title compound as a white solid (98.4 mg, 0.13 mmol, 24%). (m/z):[M+H]⁺ calcd for C₃₀H₃₉N₅O₃, 518.32; found 518.6. ¹H NMR (300 MHz,MeOD-d₃): δ (ppm) 1.14-1.28 (m, 2H), 1.39-1.53 (m, 6H), 1.52-1.62 (m,2H), 1.70-1.78 (m, 2H), 1.92-2.06 (m, 4H), 2.82-2.97 (m, 6H), 3.32-3.38(m, 2H), 3.43-3.50 (m, 1H), 3.52-3.69 (m, 2H), 4.04-4.12 (m, 1H),4.18-4.26 (m, 1H), 6.91-6.98 (m, 1H), 7.08-7.13 (m, 1H), 7.21-7.28 (m,1H), 7.45-7.50 (m, 1H), 7.73-7.77 (m, 1H), 7.81-7.87 (m, 1H), 9.02-9.32(brs, 1H).

Example 3: Synthesis of 2-isopropyl-1H-benzoimidazole-4-carboxylic acid{1-[1-(2-chlorobenzoyl) piperidin-4-ylmethyl]piperidin-4-ylmethyl}amide

To a suspension of 2-isopropyl-1H-benzoimidazole-4-carboxylic acid(1-piperidin-4-ylmethylpiperidin-4-ylmethyl)amide (2.1 g, 5.29 mmol) intetrahydrofuran (26 mL) at room temperature was addedN,N-diisopropylethylamine (2.05 g, 15.87 mmol), dichloromethane (12 mL)and N,N-dimethylformamide (5 mL). To the resulting suspension was slowlyadded o-chlorobenzoyl chloride (1.02 g, 5.82 mmol), and the reactionmixture was stirred for 0.5 h at room temperature. The solution wasconcentrated in vacuo, the resulting residue diluted with acetic acid(7.5 mL) and water (0.5 mL), and the product purified by reverse phasepreparative HPLC. The purified salt was partitioned betweendichloromethane and 1M aqueous sodium hydroxide, the organic layerremoved and the aqueous layer re-extracted with dichloromethane, and thecombined organic layers washed with brine, dried over sodium sulfate andconcentrated in vacuo to give the title compound as a white foam (1.75g, 3.26 mmol, 62%). (m/z): [M+H]⁺ calcd for C₃₀H₃₈ClN₅O₂, 536.28; found536.3. ¹H NMR (300 MHz, DMSO-d₆): 0.90 (br m, 2H), 1.24 (d, 6H), 1.45(br m, 2H), 1.68 (br m, 8H), 1.96 (m, 1H), 2.72 (br m, 5H), 3.08 (m,2H), (3.20, m, 3H), 4.40 (br m, 1H), 7.14 (t, 1H), 7.28 (m, 2H), 7.39(m, 1H), 7.49 (dd, 1H), 7.66 (dd, 1H).

Examples 4-6

Using processes similar to that of Example 3, except replacing theo-chlorobenzoyl chloride with the appropriate chloride reagent, thecompounds of Examples 4-6 were prepared.

-   Example 4 2-isopropyl-1H-benzoimidazole-4-carboxylic acid    {1-[1-(2,4-difluoro-benzoyl)piperidin-4-ylmethyl]piperidin-4-ylmethyl}amide;    (m/z): [M+H]⁺ calcd for C₃₀H₃₇F₂N₅O₂, 538.30; found 538.2. Retention    time (anal. HPLC: 2-60% MeCN/H₂O over 4 min)=2.12 min. ¹H NMR (300    MHz, DMSO-d₆): 0.92 (m, 2H), 1.30 (m, 2H), 1.38 (d, 6H), 1.53 (m,    2H), 1.60-1.90 (m, 6H), 2.07 (d, 2H), 2.73-2.85 (br m, 3H), 3.05 (t,    1H), 3.22 (septet, 1H), 3.38 (br m, 3H), 4.44 (br d, 1H), 7.10-7.50    (m, 4H), 7.62 (d, 1H), 7.77 (d, 1H), 10.10 (br s, 1H).-   Example 5 2-isopropyl-1H-benzoimidazole-4-carboxylic acid    {1-[1-(furan-2-carbonyl)-piperidin-4-ylmethyl]piperidin-4-ylmethyl}amide;    (m/z): [M+H]⁺ calcd for C₂₈H₃₇N₅O₃, 492.30; found 492.2. Retention    time (anal. HPLC: 2-65% MeCN/H₂O over 4 min)=1.68 min.-   Example 6 2-isopropyl-1H-benzoimidazole-4-carboxylic acid    {1-[1-(thiophene-2-carbonyl)piperidin-4-ylmethyl]piperidin-4-ylmethyl}amide;    (m/z): [M+H]⁺ calcd for C₂₈H₃₇N₅O₂S, 508.28; found 508.2. Retention    time (anal. HPLC: 2-65% MeCN/H₂O over 4 min)=1.94 min.

Example 7: Synthesis of 2-isopropyl-1H-benzoimidazole-4-carboxylic acid{1-[1-(2-fluoro-5-trifluoromethylbenzoylpiperidin-4-ylmethyl]piperidin-4-ylmethyl}amide

To a solution of 2-fluoro-5-trifluoromethyl benzoic acid (100 mg, 0.48mmol) in dimethylformamide (4 mL) at room temperature was addedO-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate (200 mg, 0.48 mmol). The mixture was stirred at roomtemperature for 0.25 h, then 2-isopropyl-1H-benzoimidazole-4-carboxylicacid (1-piperidin-4-ylmethylpiperidin-4-ylmethyl)amide (210 mg, 0.48mmol) and N,N-diisopropylethylamine (0.184 mL, 0.96 mmol) were added andstirring continued for a further 0.5 h. The solution was evaporated invacuo and the crude product purified by reverse phase HPLC [gradient of5-10-25% (5-10% over 10 min; 10-25% over 50 min); flow rate 15 mL/min;detection at 280 nm] to afford the bis trifluoroacetate salt of thetitle compound as a white solid (70 mg, 0.09 mmol, 18%). (m/z): [M+H]⁺calcd for C₃₁H₃₇F₄N₅O₂, 588.30; found 588.2. Retention time (anal. HPLC:2-60% MeCN/H₂O over 4 min)=2.39 min.

Example 8: Synthesis of 2-isopropyl-1H-benzoimidazole-4-carboxylic acid{1-[1-(2-fluoro-phenylcarbamoyl)piperidin-4-ylmethyl]piperidin-4-ylmethyl}-amide

2-Isopropyl-1H-benzoimidazole-4-carboxylic acid(1-piperidin-4-ylmethylpiperidin-4-ylmethyl)amide (220 mg, 0.55 mmol)was dissolved in N,N-dimethylformamide (2.0 mL) at room temperature. Tothis solution was added N,N-diisopropylethylamine (143.2 mg, 1.1 mmol)followed by o-fluorophenylisocyanate (75.4 mg, 0.55 mmol). The resultingmixture was stirred at room temperature overnight, concentrated in vacuoand the residue purified by preparative reverse-phase HPLC to afford thebis trifluoroacetate salt of the title compound as a white solid (92.6mg, 0.12 mmol, 22%). (m/z): [M+H]⁺ calcd for C₃₀H₃₉FN₆O₂, 535.32; found535.2. Retention time (anal. HPLC: 2-65% MeCN/H₂O over 4 min)=2.09 min.

Example 9: Synthesis of 2-isopropyl-1H-benzoimidazole-4-carboxylic acid[1-(1-methanesulfonylpiperidin-4-ylmethyl)piperidin-4-ylmethyl]amide

2-Isopropyl-1H-benzoimidazole-4-carboxylic acid(1-piperidin-4-ylmethylpiperidin-4-ylmethyl)amide (40 mg, 0.1 mmol) wasdissolved in N,N-dimethylformamide (1.0 mL) at room temperature. To thissolution was added N,N-diisopropylethylamine (0.175 mL, 1 mmol) followedby methanesulfonyl chloride (11.5 mg, 0.1 mmol). The mixture was stirredat room temperature for 16 h, then concentrated in vacuo and the residuepurified by preparative reverse-phase HPLC to afford the bistrifluoroacetate salt of the title compound as a white solid (27.2 mg,0.04 mmol, 40%). (m/z): [M+H]⁺ calcd for C₂₄H₃₇N₅O₃S, 476.27; found476.2. Retention time (anal. HPLC: 2-65% MeCN/H₂O over 4 min)=1.66 min.

Example 10: Synthesis of4-(4-{[(2-tert-butyl-1H-benzoimidazole-4-carbonyl)-amino]-methyl}piperidin-1-ylmethyl)piperidine-1-carboxylicAcid Methyl Ester

To the crude product of Preparation 3 (2.4 g, 5.8 mmol) indichloromethane (29 mL) at room temperature was addedN,N-diisopropylethylamine (1.5 g, 11.6 mmol). The resulting mixture wascooled to 0° C. and methyl chloroformate (660 mg, 6.98 mmol) was addeddropwise. The reaction was allowed to warm to room temperature andstirred for a further 10 min. The solution was concentrated,re-dissolved in 50% acetic acid in water, filtered and purified byreversed phase preparative HPLC. The resulting solid was dissolved indichloromethane and washed with 1M aqueous sodium hydroxide. The aqueouslayer was extracted twice with dichloromethane, and the combined organiclayers washed with brine, dried over sodium sulfate, filtered andconcentrated to give the title compound as a white foam (1.3 g, 2.8mmol, 48%). (m/z): [M+H]⁺ calcd for C₂₆H₃₉N₅O₃, 470.32, found 470.6. ¹HNMR (300 MHz, MeOD-d₃): δ (ppm) 1.02-1.16 (m, 2H), 1.49 (s, 9H),1.47-1.7 (m, 4H), 1.82-2.03 (m, 4H), 2.74-2.94 (m, 6H), 3.31-3.40 (m,2H), 3.54-3.58 (m, 2H), 3.56 (s, 3H), 3.98-4.03 (m, 2H), 7.41-7.46 (m,1H), 7.71-7.74 (m, 1H), 7.79-7.82 (m, 1H), 9.35 (brs, 1H).

Examples 11-13

Using processes similar to that of Example 10, except replacing themethyl chloroformate with the appropriate chloride reagent, thecompounds of Examples 11-13 were prepared.

-   Example 11 2-tert-butyl-1H-benzoimidazole-4-carboxylic acid    {1-[1-(2-fluoro-benzoyl)-piperidin-4-ylmethyl]piperidin-4-ylmethyl}amide;    (m/z): [M+H]⁺ calcd for C₃₁H₄₀FN₅O₂, 534.33; found 534.4. Retention    time (anal. HPLC: 2-65% MeCN/H₂O over 4 min)=2.09 min.-   Example 12 2-tert-butyl-1H-benzoimidazole-4-carboxylic acid    {1-[1-(3-methyl-benzoyl)-piperidin-4-ylmethyl]piperidin-4-ylmethyl}amide;    (m/z): [M+H]⁺ calcd for C₃₂H₄₃N₅O₂, 530.35; found 530.42. Retention    time (anal. HPLC: 2-65% MeCN/H₂O over 4 min)=2.22.-   Example 13 2-tert-butyl-1H-benzoimidazole-4-carboxylic acid    {1-[1-(4-fluorobenzoyl)-piperidin-4-ylmethyl]piperidin-4-ylmethyl}amide;    (m/z): [M+H]⁺ calcd for C₃₁H₄₀FN₅O₂, 534.33; found 534.4. Retention    time (anal. HPLC: 2-65% MeCN/H₂O over 4 min)=2.17.

Example 14: Synthesis of4-[4-({[2-(1-hydroxy-1-methylethyl)-1H-benzoimidazole-4-carbonyl]amino}methyl)piperidin-1-ylmethyl]piperidine-1-carboxylicAcid Methyl Ester

a. Preparation of2-(1-hydroxy-1-methylethyl)-1H-benzoimidazole-4-carboxylic Acid

To a solution of 2,3-diaminobenzoic acid methyl ester (1.5 g, 9.2 mmol)in 4 M HCl (50 mL) was added 2-hydroxyisobutyric acid (2.87 g, 27.6mmol). The mixture was stirred at ˜90° C. for 24 h. It was neutralizedby use of aqueous sodium hydroxide solution to pH˜3, and concentrated todryness. The residue was suspended in methanol, and filtered through afilter paper. The filtrate was concentrated and the residue was rinsedwith ether. The remaining solid residue was dissolved in ethyl acetate,and washed with brine solution. After drying over MgSO₄, the organicsolution was evaporated in vacuo, yielding the title intermediate as apale yellow oil (˜800 mg). The crude product was used in the next stepwithout further purification. (m/z): [M+H]⁺ calcd for C₁₁H₁₂N₂O₃,221.09; found 221.1. ¹H-NMR (CD₃OD) δ (ppm) 7.8 (dd, 1H), 7.7 (dd, 1H),7.2 (m, 1H), 1.3 (s, 6H).

b. Synthesis of4-[4-({[2-(1-hydroxy-1-methylethyl)-1H-benzoimidazole-4-carbonyl]amino}methyl)piperidin-1-ylmethyl]piperidine-1-carboxylicAcid Methyl Ester

To a solution of the benzoimidazole carboxylic acid product of theprevious step (0.7 g, 3.18 mmol), the aminomethylpiperidine product ofPreparation 4 as the bis-TFA salt (1.2 g, 3.13 mmol), andhydroxybenzotriazole (HOBt) (0.43 g, 3.18 mmol) in dimethylformamide (50mL) was added triethylamine (1.3 mL, 9.3 mmol) andN-Ethyl-N-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) (0.67g, 3.5 mmol). The mixture was stirred at room temperature for 12 h, andconcentrated to dryness in vacuo. The residue was partitioned betweendichloromethane (150 mL) and saturated sodium bicarbonate. The organiclayer was dried over MgSO₄, and evaporated to dryness, yielding a paleyellow oily residue. It was purified by preparative HPLC to provide thebis-trifluoroacetate salt of the title compound. (m/z): [M+H]⁺ calcd forC₂₅H₃₇N₅O₄, 472.29; found 472.5. Retention time (anal. HPLC: 5-30%MeCN/H₂O over 6 min)=3.67 min. ¹H-NMR (CD₃OD) δ (ppm) 7.9-7.8 (m, 2H),7.6-7.5 (t, 1H), 4.0 (br d, 2H), 3.6 (s, 5H), 2.9-2.75 (br m, 5H),2.05-1.9 (br d, 3H), 1.68 (m, 6H), 1.15 (m, 4H).

Example 15. Synthesis of4-[4-({[2-(2-hydroxy-1-methylethyl)-1H-benzoimidazole-4-carbonyl]amino}methyl)-piperidin-1-ylmethyl]piperidine-1-carboxylicAcid Methyl Ester

a. Preparation of2-(2-hydroxy-1-methylethyl)-1H-benzoimidazole-4-carboxylic Acid

To a solution of 2,3-diaminobenzoic acid methyl ester (2.1 g, 14.1 mmol)in 4 M HCl (90 mL) was added 2-methyl-3-hydroxypropionic acid methylester (5 g, 42.3 mmol). The mixture was stirred at ˜90° C. for 24 h. Itwas neutralized by use of aqueous sodium hydroxide solution to pH˜3, andconcentrated to dryness. The residue was suspended in methanol, andfiltered through a filter paper. After the filtrate was concentrated,the remaining solid residue was dissolved in water and washed with ethylacetate. The aqueous solution was evaporated in vacuo yielding the titleintermediate as a pale yellow oil (˜800 mg). The crude product was usedin the next step without further purification. (m/z): [M+H]⁺ calcd forC₁₁H₁₂N₂O₃, 221.09; found 221.3. ¹H-NMR (CD₃OD) δ (ppm) 8.1 (d, 1H), 7.9(m, 1H), 7.6 (t, 1H), 3.8 (m, 2H), 3.6 (m, 1H), 1.4 (d, 3H).

b. Synthesis of4-[4-({[2-(2-hydroxy-1-methylethyl)-1H-benzoimidazole-4-carbonyl]amino}methyl)piperidin-1-ylmethyl]piperidine-1-carboxylicAcid Methyl Ester

To a solution of the benzoimidazole carboxylic acid product of theprevious step (0.45 g, 1.75 mmol), the aminomethylpiperidine product ofPreparation 4 as the bis-trifluoroacetate salt (0.8 g, 1.6 mmol), andHOBt (0.237 g, 1.75 mmol) in dimethylformamide (50 mL) was addedtriethylamine (0.98 mL, 7.0 mmol) and EDC (0.353 g, 1.84 mmol). Themixture was stirred at room temperature for 12 h, and concentrated todryness under reduced pressure. The residue was partitioned betweendichloromethane (150 mL) and saturated sodium bicarbonate. The organiclayer was dried over MgSO₄, and evaporated to dryness, yielding paleyellow oily residue. It was purified by preparative HPLC, yielding thebis-trifluoroacetate salt of the title compound (0.2 g). (m/z): [M+H]⁺calcd for C₂₅H₃₇N₅O₄, 472.29; found 472.5. Retention time (anal. HPLC:10-40% MeCN/H₂O over 6 min)=3.31 min. ¹H-NMR (CD₃OD) δ (ppm) 7.9-7.8 (m,2H), 7.6-7.5 (m, 1H), 4.0 (br d, 2H), 3.85-3.7 (m, 2H), 3.6 (br s, 6H),3.3 (br, 2H), 2.9-2.6 (br m, 6H), 2.0-1.8 (br, 4H), 1.7-1.5 (m, 6H), 1.4(m, 3H), 1.1-1.0 (m, 4H).

Additional Compounds of the Invention

Using the procedures of Examples 1-13 and variations thereof, thecompounds of Tables I to IX were prepared and characterized by massspectrometry. In the following tables, blank entries denote hydrogen.

TABLE I

Example Molecular [M + H]⁺ [M + H]⁺ No. R¹ R² Formula calcd found 16 iPr—CH₂-phenyl C₃₁H₄₁N₅O₃ 532.32 532.2 17 iPr iPr C₂₇H₄₁N₅O₃ 484.32 484.218 tBu phenyl C₃₁H₄₁N₅O₃ 532.32 532.2 19 tBu —CH₂-phenyl C₃₂H₄₃N₅O₃546.34 546.4 20 tBu iPr C₂₈H₄₃N₅O₃ 498.34 498.4

TABLE II

Example Molecular [M + H]⁺ [M + H]⁺ No. R¹ R^(3a) R^(3b) R^(3c) R^(3d)R^(3e) Formula calcd found 21 tBu Cl C₃₁H₄₀ClN₅O₂ 550.29 550.6 22 iPrC₃₀H₃₉N₅O₂ 502.31 502.4 23 iPr F C₃₀H₃₈FN₅O₂ 520.30 520.2 24 iPr CH₃C₃₁H₄₁N₅O₂ 516.33 516.4 25 iPr CF₃ C₃₁H₃₈F₃N₅O₂ 570.30 570.2 26 iPr FC₃₀H₃₈FN₅O₂ 520.30 520.2 27 iPr CH₃ C₃₁H₄₁N₅O₂ 516.33 516.4 28 iPr CF₃C₃₁H₃₈F₃N₅O₂ 570.30 570.2 29 iPr Cl C₃₀H₃₈ClN₅O₂ 536.27 536.2 30 iPr CF₃C₃₁H₃₈F₃N₅O₂ 570.30 570.2 31 iPr CH₃ C₃₁H₄₁N₅O₂ 516.33 516.4 32 iPr ClC₃₀H₃₈ClN₅O₂ 536.27 536.2 33 iPr OCH₃ C₃₁H₄₁N₅O₃ 532.32 532.2 34 iPr FC₃₀H₃₈FN₅O₂ 520.30 520.2 35 iPr F F C₃₀H₃₇F₂N₅O₂ 538.29 538.2 36 iPr F FC₃₀H₃₇F₂N₅O₂ 538.29 538.2 37 iPr F F C₃₀H₃₇F₂N₅O₂ 538.29 538.2 38 iPr FF C₃₀H₃₇F₂N₅O₂ 538.29 538.2 39 iPr F F C₃₀H₃₇F₂N₅O₂ 538.29 538.2 40 iPrF Cl C₃₀H₃₇ClFN₅O₂ 554.26 554.4 41 iPr CF₃ CF₃ C₃₂H₃₇F₆N₅O₂ 638.29 638.242 iPr Cl F C₃₀H₃₇ClFN₅O₂ 554.26 554.2 43 iPr Cl Cl C₃₀H₃₇Cl₂N₅O₂ 570.23570.2 44 iPr OCF₃ C₃₁H₃₈F₃N₅O₃ 586.29 586.2 45 iPr CF₃ F C₃₁H₃₇F₄N₅O₂588.29 588.2 46 iPr Cl F C₃₀H₃₇ClFN₅O₂ 554.26 554.2 47 iPr OCH₃ ClC₃₁H₄₀ClN₅O₃ 566.28 566.2 48 iPr CN C₃₁H₃₈N₆O₂ 527.31 527.2 49 iPr Cl ClC₃₀H₃₇Cl₂N₅O₂ 570.23 570.2 50 iPr F CF₃ C₃₁H₃₇F₄N₅O₂ 588.29 588.2 51 iPrCN C₃₁H₃₈N₆O₂ 527.31 527.2 52 iPr OCHF₂ C₃₁H₃₉F₂N₅O₃ 568.30 568.8 53 tBuCl F C₃₁H₃₉ClFN₅O₂ 568.28 568.2 54 tBu Cl Cl C₃₁H₃₉Cl₂N₅O₂ 584.25 584.255 tBu CN C₃₂H₄₀N₆O₂ 541.32 541.4 56 tBu OCF₃ C₃₂H₄₀F₃N₅O₃ 600.31 600.257 tBu CF₃ F C₃₂H₃₉F₄N₅O₂ 602.30 602.2 58 tBu Cl F C₃₁H₃₉ClFN₅O₂ 568.28568.2 59 tBu OCH₃ Cl C₃₂H₄₂ClN₅O₃ 580.30 580.2 60 tBu CN C₃₂H₄₀N₆O₂541.32 541.4 61 tBu Cl Cl C₃₁H₃₉Cl₂N₅O₂ 584.25 584.2 62 tBu F CF₃C₃₂H₃₉F₄N₅O₂ 602.30 602.2 63 tBu F CF₃ C₃₂H₃₉F₄N₅O₂ 602.30 602.4 64 tBuCN C₃₂H₄₀N₆O₂ 541.32 541.2 65 tBu OCHF₂ C₃₂H₄₁F₂N₅O₃ 582.32 582.4 66 tBuC₃₁H₄₁N₅O₂ 516.33 516.2 67 tBu CH₃ C₃₂H₄₃N₅O₂ 530.34 530.4 68 tBu CF₃C₃₂H₄₀F₃N₅O₂ 584.31 584.4 69 tBu F C₃₁H₄₀FN₅O₂ 534.32 534.2 70 tBu CF₃C₃₂H₄₀F₃N₅O₂ 584.31 584.4 71 tBu Cl C₃₁H₄₀ClN₅O₂ 550.29 550.2 72 tBu CF₃C₃₂H₄₀F₃N₅O₂ 584.31 584.4 73 tBu CH₃ C₃₂H₄₃N₅O₂ 530.34 530.4 74 tBu ClC₃₁H₄₀ClN₅O₂ 550.29 550.2 75 tBu OCH₃ C₃₂H₄₃N₅O₃ 546.34 546.4 76 tBu F FC₃₁H₃₉F₂N₅O₂ 552.31 552.4 77 tBu F F C₃₁H₃₉F₂N₅O₂ 552.31 552.2 78 tBu FF C₃₁H₃₉F₂N₅O₂ 552.31 552.2 79 tBu F F C₃₁H₃₉F₂N₅O₂ 552.31 552.4 80 tBuF F C₃₁H₃₉F₂N₅O₂ 552.31 552.4 81 tBu F F C₃₁H₃₉F₂N₅O₂ 552.31 552.2 82tBu F Cl C₃₁H₃₉ClFN₅O₂ 568.28 568.2 83 tBu CF₃ CF₃ C₃₃H₃₉F₆N₅O₂ 652.30652.2 84 iPr OCF₃ C₃₁H₃₈F₃N₅O₃ 586.29 586.2 85 iPr OCF₃ C₃₁H₃₈F₃N₅O₃586.29 586.2 86 tBu OCF₃ C₃₂H₄₀F₃N₅O₃ 600.31 600.2 87 tBu OCF₃C₃₂H₄₀F₃N₅O₃ 600.31 600.2

TABLE III

Ex- [M + [M + ample Molecular H]⁺ H]⁺ No. R¹ R³ Formula calcd found  88iPr N(CH₃)₂ C₂₆H₄₀N₆O₂ 469.32 469.4  89 iPr morpholin-1-yl C₂₈H₄₂N₆O₃511.33 511.4  90 iPr CH₃ C₂₅H₃₇N₅O₂ 440.30 440.2  91 iPrtetrahydrofuran- C₂₈H₄₁N₅O₃ 496.32 496.4 2-yl  92 iPr —CH₂- C₂₉H₃₉N₅O₂S522.28 522.2 thiophen-3-yl  93 iPr 2,2- C₂₉H₄₅N₅O₂ 496.36 496.4dimethylpropyl  94 iPr —CH₂-thiophen- C₂₉H₃₉N₅O₂S 522.28 522.2 2-yl  95iPr cyclohexyl C₃₀H₄₅N₅O₂ 508.36 508.4  96 iPr (S)-1- C₂₈H₄₃N₅O₂ 482.34482.4 methylpropyl  97 iPr —CH₂-naphth- C₃₅H₄₃N₅O₂ 566.34 566.4 1-yl  98iPr cyclopentyl C₃₀H₄₅N₅O₂ 508.36 508.4  99 iPr (R)- C₂₈H₄₁N₅O₃ 496.32496.4 tetrahydrofuran- 2-yl 100 tBu furan-2-yl C₂₉H₃₉N₅O₃ 506.31 506.2101 tBu —CH₂-thiophen- C₃₀H₄₁N₅O₂S 536.30 536.2 3-yl 102 tBu 2,2-C₃₀H₄₇N₅O₂ 510.37 510.4 dimethylpropyl 103 tBu —CH₂-thiophen-C₃₀H₄₁N₅O₂S 536.30 536.2 2-yl 104 tBu (S)-1- C₂₉H₄₅N₅O₂ 496.36 496.4methylpropyl 105 tBu —CH₂-naphth- C₃₆H₄₅N₅O₂ 580.36 580.4 1-yl 106 tBu(R)- C₂₉H₄₃N₅O₃ 510.34 510.4 tetrahydrofuran- 2-yl 107 tBu (S)-4-oxo-C₂₈H₄₀N₆O₃ 509.32 510.4 azetidin-2-yl 108 tBu pyridin-2-yl C₃₁H₄₂N₆O₂531.34 531.2

TABLE IV

Example Molecular [M + H]⁺ [M + H]⁺ No. R¹ R^(5a) R^(5b) R^(5c) R^(5d)R^(5e) Formula calcd found 109 iPr CH₃ C₃₁H₄₂N₆O₂ 531.34 531.4 110 iPr FC₃₀H₃₉FN₆O₂ 535.31 535.2 111 iPr CF₃ C₃₁H₃₉F₃N₆O₂ 585.31 585.2 112 iPrOCF₃ C₃₁H₃₉F₃N₆O₃ 601.30 601.2 113 iPr OCHF₂ C₃₁H₄₀F₂N₆O₃ 583.31 583.2114 iPr C₃₀H₄₀N₆O₂ 517.32 517.4 115 iPr CH₃ CH₃ C₃₂H₄₄N₆O₂ 545.35 545.4116 iPr OCF₃ C₃₁H₃₉F₃N₆O₃ 601.30 601.2 117 iPr tBu C₃₄H₄₈N₆O₂ 573.38573.4 118 iPr Cl C₃₀H₃₉ClN₆O₂ 551.28 551.2 119 tBu Cl C₃₁H₄₁ClN₆O₂565.30 565.2 120 tBu CH₃ C₃₂H₄₄N₆O₂ 545.35 545.5 121 tBu F C₃₁H₄₁FN₆O₂549.33 549.2 122 tBu CF₃ C₃₂H₄₁F₃N₆O₂ 599.32 599.2 123 tBu OCF₃C₃₂H₄₁F₃N₆O₃ 615.32 615.2 124 tBu OCHF₂ C₃₂H₄₂F₂N₆O₃ 597.33 597.4 125tBu F C₃₁H₄₁FN₆O₂ 549.33 549.2 126 tBu C₃₁H₄₂N₆O₂ 531.34 531.4 127 tBuCH₃ CH₃ C₃₃H₄₆N₆O₂ 559.37 559.4 128 tBu OCF₃ C₃₂H₄₁F₃N₆O₃ 615.32 615.2129 tBu tBu C₃₅H₅₀N₆O₂ 587.40 587.4

TABLE V

Example Molecular [M + H]⁺ [M + H]⁺ No. R¹ R⁶ R⁷ R^(8a) R^(8b) R^(8c)R^(8d) Formula calcd found 130 iPr (S)—OH C₃₁H₄₁N₅O₃ 532.32 532.2 131iPr oxo C₃₁H₃₉N₅O₃ 530.31 530.2 132 iPr Cl C₃₁H₄₀ClN₅O₂ 550.29 550.2 133iPr (S)—CH₃ C₃₂H₄₃N₅O₂ 530.34 530.4 134 iPr —(CH₂)₂— C₃₃H₄₃N₅O₂ 542.34542.4 135 iPr F F C₃₁H₃₉F₂N₅O₂ 552.31 552.2 136 iPr F C₃₁H₄₀FN₅O₂ 534.32534.2 137 iPr Cl C₃₁H₄₀ClN₅O₂ 550.29 551.2 138 iPr F F C₃₁H₃₉F₂N₅O₂552.31 552.2 139 iPr F F C₃₁H₃₉F₂N₅O₂ 552.31 553.2 140 iPr C₃₁H₄₁N₅O₂516.33 516.4 141 tBu (S)—OH C₃₂H₄₃N₅O₃ 546.34 546.4 142 tBu FC₃₂H₄₂FN₅O₂ 548.33 548.2 143 tBu oxo C₃₂H₄₁N₅O₃ 544.32 544.4 144 tBu ClC₃₂H₄₂ClN₅O₂ 564.30 565.2 145 tBu CH₃ 2-methyl- C₃₇H₅₃N₅O₂ 600.42 600.4propyl 146 tBu (S)—CH₃ C₃₃H₄₅N₅O₂ 544.36 544.4 147 tBu —(CH₂)₂—C₃₄H₄₅N₅O₂ 556.36 556.4 148 tBu Cl Cl C₃₂H₄₁Cl₂N₅O₂ 598.26 599.2 149 tBuF F C₃₂H₄₁F₂N₅O₂ 566.32 566.2 150 tBu F C₃₂H₄₂FN₅O₂ 548.33 548.4 151 tBuCF₃ C₃₃H₄₂F₃N₅O₂ 598.33 598.4 152 tBu CF₃ C₃₃H₄₂F₃N₅O₂ 598.33 598.2 153tBu Cl C₃₃H₄₂ClN₅O₂ 564.30 564.2 154 tBu F F C₃₂H₄₁F₂N₅O₂ 566.32 566.2155 tBu F F C₃₂H₄₁F₂N₅O₂ 566.32 566.4 156 tBu C₃₂H₄₃N₅O₂ 530.34 530.4

TABLE VI

Ex- [M + [M + ample Molecular H]⁺ H]⁺ No. R¹ R⁷ R^(8a) Formula calcdfound 157 iPr (R)—OH C₃₁H₄₇N₅O₃ 538.37 538.4 158 iPr C₃₁H₄₇N₅O₂ 522.37522.4 159 tBu (R)—OH C₃₂H₄₉N₅O₃ 552.38 552.4 160 tBu C₃₂H₄₉N₅O₂ 536.39536.4

TABLE VII

Ex- [M + [M + ample Molecular H]⁺ H]⁺ No. R¹ R⁹ R^(10a) R^(10b) Formulacalcd found 161 iPr CH₃ C₃₂H₄₃N₅O₃ 546.34 546.4 162 iPr Cl ClC₃₁H₃₉Cl₂N₅O₃ 600.24 601.2 163 iPr CH₃ Cl C₃₂H₄₂ClN₅O₃ 580.30 581.2 164iPr CH₃ C₃₂H₄₃N₅O₃ 546.34 546.4 165 tBu CH₃ C₃₃H₄₅N₅O₃ 560.35 560.4 166tBu Cl Cl C₃₂H₄₁Cl₂N₅O₃ 614.26 615.2 167 tBu CH₃ Cl C₃₃H₄₄ClN₅O₃ 594.31595.2 168 tBu CH₃ C₃₃H₄₅N₅O₃ 560.35 560.4

TABLE VIII

Ex- [M + [M + ample Molecular H]⁺ H]⁺ No. R¹ R¹¹ Formula calcd found 169iPr CH₃ C₂₄H₃₇N₅O₃S 476.26 476.2 170 iPr 2,4- C₂₈H₄₀N₆O₄S 557.28 557.2dimethylisoxazol- 2yl 171 iPr —CH₂-phenyl C₃₀H₄₁N₅O₃S 552.29 552.2 172tBu 2,4- C₂₉H₄₂N₆O₄S 571.30 571.2 dimethylisoxazol- 2yl 173 tBu—CH₂-phenyl C₃₁H₄₃N₅O₃S 566.31 566.2

TABLE IX

Example Molecular [M + H]⁺ [M + H]⁺ No. R¹ R^(11a) R^(11b) R^(11c)R^(11d) Formula calcd found 174 iPr CF₃ C₃₀H₃₈F₃N₅O₃S 606.27 606.2 175iPr CN C₃₀H₃₈N₆O₃S 563.27 563.2 176 iPr OCH₃ C₃₀H₄₁N₅O₄S 568.29 568.2177 iPr Cl C₂₉H₃₈ClN₅O₃S 572.24 572.2 178 iPr F C₂₉H₃₈FN₅O₃S 556.27556.2 179 iPr CF₃ C₃₀H₃₈F₃N₅O₃S 606.27 606.2 180 iPr iPr C₃₂H₄₅N₅O₃S580.32 580.4 181 iPr Cl C₂₉H₃₈ClN₅O₃S 572.24 572.2 182 iPr CH₃ FC₃₀H₄₀FN₅O₃S 570.28 570.2 183 iPr Cl F C₂₉H₃₇ClFN₅O₃S 590.23 590.2 184iPr CH₃ Cl C₃₀H₄₀ClN₅O₃S 586.25 586.2 185 iPr tBu C₃₃H₄₇N₅O₃S 594.34594.4 186 iPr OCH₃ Cl C₃₀H₄₀ClN₅O₄S 602.25 602.2 187 iPr ClC₂₉H₃₈ClN₅O₃S 572.24 572.2 188 iPr C₂₉H₃₉N₅O₃S 538.28 538.2 189 iPr FC₂₉H₃₈FN₅O₃S 556.27 556.2 190 iPr CH₃ C₃₀H₄₁N₅O₃S 552.29 552.2 191 iPrCH₃ C₃₀H₄₁N₅O₃S 552.29 552.2 192 iPr CF₃ C₃₀H₃₈F₃N₅O₃S 606.27 606.2 193iPr CH₃ C₃₀H₄₁N₅O₃S 552.29 552.2 194 tBu CN C₃₁H₄₀N₆O₃S 577.29 577.2 195tBu CF₃ C₃₁H₄₀F₃N₅O₃S 620.28 620.2 196 tBu iPr C₃₃H₄₇N₅O₃S 594.34 594.4197 tBu Cl C₃₀H₄₀ClN₅O₃S 586.25 586.2 198 tBu CH₃ F C₃₁H₄₂FN₅O₃S 584.30584.2 199 tBu Cl F C₃₀H₃₉ClFN₅O₃S 604.24 604.2 200 tBu CH₃ ClC₃₁H₄₂ClN₅O₃S 600.27 600.2 201 tBu tBu C₃₄H₄₉N₅O₃S 608.36 608.4 202 tBuOCH₃ Cl C₃₁H₄₂ClN₅O₄S 616.26 616.2 203 tBu CH₃ C₃₁H₄₃N₅O₃S 566.31 566.4204 tBu CH₃ C₃₁H₄₃N₅O₃S 566.31 566.2 205 tBu CF₃ C₃₁H₄₀F₃N₅O₃S 620.28620.2 206 tBu CH₃ C₃₁H₄₃N₅O₃S 566.31 566.2 207 tBu CF₃ C₃₁H₄₀F₃N₅O₃S620.28 620.2 208 tBu OCH₃ C₃₁H₄₃N₅O₄S 582.30 582.2 209 tBu ClC₃₀H₄₀ClN₅O₃S 586.25 586.2 210 tBu F C₃₀H₄₀FN₅O₃S 570.28 570.2 211 tBuCl C₃₀H₄₀ClN₅O₃S 586.25 586.2 212 tBu C₃₀H₄₁N₅O₃S 552.29 552.2 213 tBu FC₃₀H₄₀FN₅O₃S 570.28 570.2

Example 214: Alternate Synthesis of4-(4-{[(2-isopropyl-1H-benzoimidazole-4-carbonyl)-amino]methyl}piperidin-1-ylmethyl)piperidine-1-carboxylicAcid Methyl Ester

a. Preparation of 4-hydroxymethyl-piperidine-1-carboxylic Acid MethylEster

4-Hydroxymethylpiperidine (1.0 g, 8.6 mmol) was dissolved in water (15mL) and cooled to 0° C. To this solution was added dropwise a solutionof potassium carbonate (4.8 g, 34.7 mmol) in water (10 mL), followed bymethyl chloroformate (2.68 mL, 34.7 mmol). The mixture was stirredvigorously and allowed to warm to room temperature over 2 h. Afterstirring overnight (16 h), the reaction mixture was acidified with 6Maqueous hydrochloric acid and extracted with dichloromethane (3×60 mL).The extracts were combined, dried over sodium sulfate and filtered. Thefiltrate was evaporated to yield the title intermediate (1.4 g, 8.1mmol, 93%) as a colorless oil. (m/z): C₈H₁₅NO₃, calcd. 173.11; found156.2 [M−H₂O+H]⁺. ¹H NMR (300 MHz, DMSO-d₆): δ (ppm) 0.98 (m, 2H), 1.52(m, 1H), 1.63 (br d, 2H), 2.72 (br m, 2H), 3.23 (d, 2H), 3.56 (s, 3H),3.95 (br d, 2H), 4.48 (br s, 1H).

b. Preparation of 4-formylpiperidine-1-carboxylic Acid Methyl Ester

To a solution of oxalyl chloride (4.1 mL, 8.2 mmol) in dichloromethane(4 mL) at −78° C. was added dropwise a solution of dimethylsulfoxide(1.2 mL, 16.4 mmol) in dichloromethane (4 mL). After stirring for 5 min,a solution of 4-hydroxymethyl-piperidine-1-carboxylic acid methyl ester(1.3 g, 7.5 mmol) in dichloromethane (5 mL) was added. The resultingsolution was stirred for another 5 min, then triethylamine (5.2 mL, 37.3mmol) was added and the mixture allowed to warm to −10° C. Afterstirring for 1 h, dichloromethane (100 mL) was added, and the organiclayer was washed with 1M aqueous phosphoric acid, 1M aqueous sodiumhydroxide, and brine. The solution was dried over sodium sulfate thenevaporated to afford the title intermediate as a wheat colored oil (1.0g, 5.8 mmol, 78%). ¹H NMR (300 MHz, DMSO-d₆): δ (ppm) 1.36 (m, 2H), 1.83(m, 2H), 2.48 (br m, 1H), 2.93 (br t, 2H), 3.56 (s, 3H), 3.80 (br d,2H), 9.56 (s, 1H).

c. Synthesis of4-(4-{[(2-isopropyl-1H-benzoimidazole-4-carbonyl)-amino]methyl}piperidin-1-ylmethyl)piperidine-1-carboxylicAcid Methyl Ester

2-Isopropyl-1H-benzoimidazole-4-carboxylic acid(piperidin-4-ylmethyl)amide, (bis TFA salt; 1.1 g, 2.0 mmol) wassuspended in dichloromethane (20 mL) and N,N-di-isopropylethylamine(0.72 mL, 4.0 mmol) was added. When the suspension became a clearsolution, acetic acid (0.13 mL, 2.0 mmol) was added, followed by asolution of 4-formylpiperidine-1-carboxylic acid methyl ester (0.54 g,3.1 mmol) in dichloromethane (20 mL). After stirring for 5 minutes atroom temperature, sodium triacetoxyborohydride (0.628 g, 3.1 mmol) wasadded, and the reaction stirred for an additional 1 h. The aqueous layerwas then made alkaline with 1M aqueous sodium hydroxide (35 mL) andextracted with dichloromethane (2×20 mL). The combined organic layerswere washed with brine, dried over sodium sulfate and evaporated toyield crude product as a brown solid (1.41 g).

The crude product was purified via preparative HPLC (reverse phase)[gradient of 5-10-25%: 5% MeCN/water (0.1% TFA) to 10% MeCN linear over10 min; 10% MeCN to 25% MeCN linear over 50 min; flow rate=15 mL/min;detection at 280 nm] to provide the title compound as the bistrifluoroacetate salt, which was then lyophilized. A mixture of 1Msodium hydroxide and dichloromethane (1:1, 100 mL) was added to thelyophilized bis trifluoroacetate salt. The organic layer was dried oversodium sulfate, filtered, and evaporated, and the resulting solid waslyophilized to provide the title compound as a white solid (0.93 g, 2mmol, 98% yield, purity 97.5%). (m/z): [M+H]⁺ calcd for C₂₅H₃₇N₅O₃,456.30; found 456.3. Retention time (anal. HPLC: 2-50% MeCN/H₂O over 6min)=3.06 min. ¹H NMR (300 MHz, DMSO-d₆): 0.92 (m, 2H), 1.30 (m, 2H),1.38 (d, 6H), 1.53 (m, 1H), 1.60-1.90 (m, 7H), 2.07 (d, 2H), 2.73 (br m,2H), 2.83 (br d, 2H), 3.22 (septet, 1H), 3.33 (t, 2H), 3.56 (s, 3H),3.93 (br d, 2H), 7.23 (t, 1H), 7.62 (d, 1H), 7.77 (d, 1H), 10.10 (br s,1H).

Example 215: Synthesis of Crystalline4-(4-{[(2-isopropyl-1H-benzoimidazole-4-carbonyl)-amino]methyl}piperidin-1-ylmethyl)piperidine-1-carboxylicAcid Methyl Ester

4-(4-[(2-isopropyl-1H-benzoimidazole-4-carbonyl)-amino]methylpiperidin-1-ylmethyl)piperidine-1-carboxylic acid methyl ester inamorphous solid form, prepared according to the process of Example 214(300 mg) was dissolved in acetonitrile (15 mL), mixed until completedissolution, and exposed to the atmosphere resulting in partialevaporation. Crystals were observed to have nucleated within 2 h.Chemical composition of the crystals was confirmed by ¹H NMR, liquidchromatography/mass spectrometry (LC/MS), and x-ray structure analysis.Crystalline nature of the solid product was confirmed by powder x-raydiffraction, differential scanning calorimetry, and x-ray structureanalysis.

Example 216: Synthesis of Crystalline4-(4-{[(2-isopropyl-1H-benzoimidazole-4-carbonyl)-amino]methyl}piperidin-1-ylmethyl)piperidine-1-carboxylicAcid Methyl Ester

a. Preparation of 4-hydroxymethyl-piperidine-1-carboxylic Acid MethylEster

4-Hydroxymethylpiperidine (47.6 g, 1.0 eq) and water (300 mL) werecharged to a flask. The resulting mixture was cooled to 0-10° C.Potassium carbonate (85.7 g, 1.5 eq) dissolved in water (150 mL) andmethyl chloroformate (38.4 mL, 1.1 eq) were added while maintaining thetemperature at below 10° C. When the addition was complete, the reactionmixture was warmed up to 20-30° C. for 1 hour. After the reaction wascomplete, dichloromethane (500 mL) was added to the reaction mixture.The organic layer was collected and washed with 1 M phosphoric acidsolution (200 mL), saturated sodium bicarbonate solution (200 mL) andsaturated sodium chloride solution (200 mL). The organic layer was driedover sodium sulfate (50 g, 1 w/w eq) and then distilled under vacuum toproduce the title intermediate. (67.0 g, 90% yield)

b. Preparation of 4-formylpiperidine-1-carboxylic Acid Methyl Ester

4-Hydroxymethylpiperidine-1-carboxylic acid methyl ester (34.7 g, 1.0eq) was dissolved in dichloromethane and cooled to 0-10° C. A solutionof sodium bicarbonate (2.35 g, 0.14 eq) and sodium bromide (2.40 g, 0.10eq) in water (100 mL) was added over 15 min while maintaining thetemperature at 0-10° C. 2,2,6,6-Tetramethyl-1-piperidinyloxy freeradical (TEMPO) (0.32 g, 0.01 eq) was added to the mixture, followed by10-13% w/v sodium hypochlorite solution (135 mL, 1.1 eq) over 1 h withgood agitation while maintaining the temperature at 0-10° C. After thereaction was complete, the layers were separated and the organic layerwashed with water (150 mL) and dried over sodium sulfate (30 g, 1 w/weq). The solvent was removed by distillation to provide the titleintermediate. (31.0 g, 90% yield)

c. Preparation of 2-isopropyl-1H-benzoimidazole-4-carboxylic acid(piperidin-4-ylmethyl)amide

Trifluoroacetic acid (56.0 mL, 10 eq) was added to a flask containing a˜5° C. solution of4-{[(2-isopropyl-1H-benzoimidazole-4-carbonyl)amino]methyl}-piperidine-1-carboxylicacid tert-butyl ester (30.0 g, 1.0 eq) in dichloromethane (300 mL) whilemaintaining the temperature below 10° C. The resulting mixture wasstirred at 20-30° C. for 2 h. When the reaction was complete,triethylamine (73.2 mL, 7.0 eq) and acetic acid (4.3 mL, 1.0 eq) wereadded to provide a solution of the title intermediate with an apparentpH of approximately 4 that was used directly in the next step.

d. Synthesis of4-(4-{[(2-isopropyl-1H-benzoimidazole-4-carbonyl)-amino]methyl}piperidin-1-ylmethyl)piperidine-1-carboxylicAcid Methyl Ester

4-Formylpiperidine-1-carboxylic acid methyl ester (25.7 g, 2.0 eq) wasadded to the solution prepared in the previous step while maintainingthe temperature at 20-30° C. After stirring for 30 min, sodiumtriacetoxyborohydride (24.3 g, 1.5 eq) was added while maintaining thetemperature at 20-30° C. The reaction mixture was stirred at 20-30° C.for 30 min. After the reaction was complete, 1 M hydrochloric acid (300mL) was added to quench the reaction. The product-containing aqueouslayer was collected and washed with dichloromethane (150 mL). Theaqueous layer was treated with activated carbon (Darco G60, 6 g, 20%w/w) to remove color. The suspension was stirred for 1 hr, and thenfiltered through a bed of Celite. Dichloromethane (300 mL) was added tothe aqueous solution and the product free-based using 4 N sodiumhydroxide by adjusting the pH of the aqueous layer to 12-13. The organiclayer was collected and washed with water (300 mL). The organic layerwas distilled at 80° C. and solvent exchanged with acetonitrile (2×300mL), to remove dichloromethane and residual triethylamine. The solidswere suspended in acetonitrile (600 mL), and the mixture heated untilthe solids were dissolved (˜75° C.). The solution was cooled untilnucleation occurred (˜55-65° C.) and held for 1 h. The slurry was cooledto 20° C. over 2 h, and then to 0-5° C. over 30 min, followed bystirring at 0-5° C. for 30 min. The solids were filtered and washed withcold acetonitrile (60 mL). The wet cake was dried under vacuum at 60° C.for 6 h to provide the title compound. (28.3 g, 85% yield).

Assay 1: Radioligand Binding Assay on 5-HT_(4(c)) Human Receptors

a. Membrane Preparation 5-HT_(4(c))

HEK-293 (human embryonic kidney) cells stably-transfected with human5-HT_(4(c)) receptor cDNA (Bmax=˜6.0 pmol/mg protein, as determinedusing [³H]-GR113808 membrane radioligand binding assay) were grown inT-225 flasks in Dulbecco's Modified Eagles Medium (DMEM) containing4,500 mg/L D-glucose and pyridoxine hydrochloride (GIBCO-InvitrogenCorp., Carlsbad Calif.: Cat #11965) supplemented with 10% fetal bovineserum (FBS) (GIBCO-Invitrogen Corp.: Cat #10437), 2 mM L-glutamine and(100 units) penicillin-(100 μg) streptomycin/ml (GIBCO-Invitrogen Corp.:Cat #15140) in a 5% CO₂, humidified incubator at 37° C. Cells were grownunder continuous selection pressure by the addition of 800 μg/mLgeneticin (GIBCO-Invitrogen Corp.: Cat #10131) to the medium.

Cells were grown to roughly 60-80% confluency (<35 subculture passages).At 20-22 hours prior to harvesting, cells were washed twice and fed withserum-free DMEM. All steps of the membrane preparation were performed onice. The cell monolayer was lifted by gentle mechanical agitation andtrituration with a 25 mL pipette. Cells were collected by centrifugationat 1000 rpm (5 min).

For the membrane preparation, cell pellets were resuspended in ice-cold50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid (HEPES), pH7.4 (membrane preparation buffer) (40 mL/total cell yield from 30-40T225 flasks) and homogenized using a polytron disrupter (setting 19,2×10 s) on ice. The resultant homogenates were centrifuged at 1200 g for5 min at 4° C. The pellet was discarded and the supernatant centrifugedat 40,000 g (20 min). The pellet was washed once by resuspension withmembrane preparation buffer and centrifugation at 40,000 g (20 min). Thefinal pellet was resuspended in 50 mM HEPES, pH 7.4 (assay buffer)(equivalent 1 T225 flask/1 mL). Protein concentration of the membranesuspension was determined by the method of Bradford (Bradford, 1976).Membranes were stored frozen in aliquots at −80° C.

b. Radioligand Binding Assays

Radioligand binding assays were performed in 1.1 mL 96-deep wellpolypropylene assay plates (Axygen) in a total assay volume of 400 μLcontaining 2 μg membrane protein in 50 mM HEPES pH 7.4, containing0.025% bovine serum albumin (BSA). Saturation binding studies fordetermination of K_(d) values of the radioligand were performed using[³H]-GR113808 (Amersham Inc., Bucks, UK: Cat # TRK944; specific activity˜82 Ci/mmol) at 8-12 different concentrations ranging from 0.001 nM-5.0nM. Displacement assays for determination of pK_(i) values of compoundswere performed with [³H]-GR113808 at 0.15 nM and eleven differentconcentrations of compound ranging from 10 pM-100 μM.

Test compounds were received as 10 mM stock solutions in DMSO anddiluted to 400 μM into 50 mM HEPES pH 7.4 at 25° C., containing 0.1%BSA, and serial dilutions (1:5) then made in the same buffer.Non-specific binding was determined in the presence of 1 μM unlabeledGR113808. Assays were incubated for 60 min at room temperature, and thenthe binding reactions were terminated by rapid filtration over 96-wellGF/B glass fiber filter plates (Packard BioScience Co., Meriden, Conn.)presoaked in 0.3% polyethyleneimine. Filter plates were washed threetimes with filtration buffer (ice-cold 50 mM HEPES, pH7.4) to removeunbound radioactivity. Plates were dried, 35 μL Microscint-20 liquidscintillation fluid (Packard BioScience Co., Meriden, Conn.) was addedto each well and plates were counted in a Packard Topcount liquidscintillation counter (Packard BioScience Co., Meriden, Conn.).

Binding data were analyzed by nonlinear regression analysis with theGraphPad Prism Software package (GraphPad Software, Inc., San Diego,Calif.) using the 3-parameter model for one-site competition. The BOTTOM(curve minimum) was fixed to the value for nonspecific binding, asdetermined in the presence of 1 μM GR113808. K_(i) values for testcompounds were calculated, in Prism, from the best-fit IC₅₀ values, andthe K_(d) value of the radioligand, using the Cheng-Prusoff equation(Cheng and Prusoff, Biochemical Pharmacology, 1973, 22, 3099-108):K_(i)=IC₅₀/(1+[L]/K_(d)) where [L]=concentration [³H]-GR113808. Resultsare expressed as the negative decadic logarithm of the K_(i) values,pK_(i).

Test compounds having a higher pK_(i) value in this assay have a higherbinding affinity for the 5-HT₄ receptor. The compounds of the inventionwhich were tested in this assay had a pK_(i) value ranging from about7.0 to about 10.0.

Assay 2: Radioligand Binding Assay on 5-HT_(3A) Human Receptors:Determination of Receptor Subtype Selectivity

a. Membrane Preparation 5-HT_(3A)

HEK-293 (human embryonic kidney) cells stably-transfected with human5-HT_(3A) receptor cDNA were obtained from Dr. Michael Bruess(University of Bonn, GDR) (Bmax=˜9.0 pmol/mg protein, as determinedusing [³H]-GR65630 membrane radioligand binding assay). Cells were grownin T-225 flasks or cell factories in 50% Dulbecco's Modified EaglesMedium (DMEM) (GIBCO-Invitrogen Corp., Carlsbad, Calif.: Cat #11965) and50% Ham's F12 (GIBCO-Invitrogen Corp.: Cat #11765) supplemented with 10%heat inactivated fetal bovine serum (FBS) (Hyclone, Logan, Utah: Cat #SH30070.03) and (50 units) penicillin-(50 μg) streptomycin/ml(GIBCO-Invitrogen Corp.: Cat #15140) in a 5% CO₂, humidified incubatorat 37° C.

Cells were grown to roughly 70-80% confluency 35 subculture passages).All steps of the membrane preparation were performed on ice. To harvestthe cells, the media was aspirated and cells were rinsed with Ca²⁺,Mg²⁺-free Dulbecco's phosphate buffered saline (dPBS). The cellmonolayer was lifted by gentle mechanical agitation. Cells werecollected by centrifugation at 1000 rpm (5 min). Subsequent steps of themembrane preparation followed the protocol described above for themembranes expressing 5-HT_(4(c)) receptors.

b. Radioligand Binding Assays

Radioligand binding assays were performed in 96-well polypropylene assayplates in a total assay volume of 200 μL containing 1.5-2 μg membraneprotein in 50 mM HEPES pH 7.4, containing 0.025% BSA assay buffer.Saturation binding studies for determination of K_(d) values of theradioligand were performed using [³H]-GR65630 (PerkinElmer Life SciencesInc., Boston, Mass.: Cat # NET1011, specific activity ˜85 Ci/mmol) attwelve different concentrations ranging from 0.005 nM to 20 nM.Displacement assays for determination of pK_(i) values of compounds wereperformed with [³H]-GR65630 at 0.50 nM and eleven differentconcentrations of compound ranging from 10 pM to 100 μM. Compounds werereceived as 10 mM stock solutions in DMSO (see section 3.1), diluted to400 μM into 50 mM HEPES pH 7.4 at 25° C., containing 0.1% BSA, andserial (1:5) dilutions then made in the same buffer. Non-specificbinding was determined in the presence of 10 μM unlabeled MDL72222.Assays were incubated for 60 min at room temperature, then the bindingreactions were terminated by rapid filtration over 96-well GF/B glassfiber filter plates (Packard BioScience Co., Meriden, Conn.) presoakedin 0.3% polyethyleneimine. Filter plates were washed three times withfiltration buffer (ice-cold 50 mM HEPES, pH7.4) to remove unboundradioactivity. Plates were dried, 35 μL Microscint-20 liquidscintillation fluid (Packard BioScience Co., Meriden, Conn.) was addedto each well and plates were counted in a Packard Topcount liquidscintillation counter (Packard BioScience Co., Meriden, Conn.).

Binding data were analyzed using the non-linear regression proceduredescribed above to determine K_(i) values. The BOTTOM (curve minimum)was fixed to the value for nonspecific binding, as determined in thepresence of 10 μM MDL72222. The quantity [L] in the Cheng-Prusoffequation was defined as the concentration [³H]-GR65630.

Selectivity for the 5-HT₄ receptor subtype with respect to the 5-HT₃receptor subtype was calculated as the ratioK_(i)(5-HT_(3A))/K_(i)(5-HT_(4(c)). The compounds of the invention whichwere tested in this assay had a 5-HT₄/5-HT₃ receptor subtype selectivityranging from about 4000 to upwards of 400,000.

Assay 3: Whole-cell cAMP Accumulation Flashplate Assay with HEK-293Cells Expressing Human 5-HT_(4(c)) Receptors

In this assay, the functional potency of a test compound was determinedby measuring the amount of cyclic AMP produced when HEK-293 cellsexpressing 5-HT₄ receptors were contacted with different concentrationsof test compound.

a. Cell Culture

HEK-293 (human embryonic kidney) cells stably-transfected with clonedhuman 5-HT_(4(c)) receptor cDNA were prepared expressing the receptor attwo different densities: (1) at a density of about 0.5-0.6 pmol/mgprotein, as determined using a [³H]-GR113808 membrane radioligandbinding assay, and (2) at a density of about 6.0 pmol/mg protein. Thecells were grown in T-225 flasks in Dulbecco's Modified Eagles Medium(DMEM) containing 4,500 mg/L D-glucose (GIBCO-Invitrogen Corp.: Cat#11965) supplemented with 10% fetal bovine serum (FBS) (GIBCO-InvitrogenCorp.: Cat #10437) and (100 units) penicillin-(100 μg) streptomycin/ml(GIBCO-Invitrogen Corp.: Cat #15140) in a 5% CO₂, humidified incubatorat 37° C. Cells were grown under continuous selection pressure by theaddition of geneticin (800 μg/mL: GIBCO-Invitrogen Corp.: Cat #10131) tothe medium.

b. Cell Preparation

Cells were grown to roughly 60-80% confluency. Twenty to twenty-twohours prior to assay, cells were washed twice, and fed, with serum-freeDMEM containing 4,500 mg/L D-glucose (GIBCO-Invitrogen Corp.: Cat#11965). To harvest the cells, the media was aspirated and 10 mL Versene(GIBCO-Invitrogen Corp.: Cat #15040) was added to each T-225 flask.Cells were incubated for 5 min at RT and then dislodged from the flaskby mechanical agitation. The cell suspension was transferred to acentrifuge tube containing an equal volume of pre-warmed (37° C.) dPBSand centrifuged for 5 min at 1000 rpm. The supernatant was discarded andthe pellet was re-suspended in pre-warmed (37° C.) stimulation buffer(10 mL equivalent per 2-3 T-225 flasks). This time was noted and markedas time zero. The cells were counted with a Coulter counter (count above8 μm, flask yield was 1-2×10⁷ cells/flask). Cells were resuspended at aconcentration of 5×10⁵ cells/ml in pre-warmed (37° C.) stimulationbuffer (as provided in the flashplate kit) and preincubated at 37° C.for 10 min.

cAMP assays were performed in a radioimmunoassay format using theFlashplate Adenylyl Cyclase Activation Assay System with ¹²⁵I-cAMP(SMP004B, PerkinElmer Life Sciences Inc., Boston, Mass.), according tothe manufacturer's instructions.

Cells were grown and prepared as described above. Final cellconcentrations in the assay were 25×10³ cells/well and the final assayvolume was 100 μL. Test compounds were received as 10 mM stock solutionsin DMSO, diluted to 400 μM into 50 mM HEPES pH 7.4 at 25° C., containing0.1% BSA, and serial (1:5) dilutions then made in the same buffer.Cyclic AMP accumulation assays were performed with 11 differentconcentrations of compound ranging from 10 pM to 100 μM (final assayconcentrations). A 5-HT concentration-response curve (10 pM to 100 μM)was included on every plate. The cells were incubated, with shaking, at37° C. for 15 min and the reaction terminated by addition of 100 μl ofice-cold detection buffer (as provided in the flashplate kit) to eachwell. The plates were sealed and incubated at 4° C. overnight. Boundradioactivity was quantified by scintillation proximity spectroscopyusing the Topcount (Packard BioScience Co., Meriden, Conn.).

The amount of cAMP produced per mL of reaction was extrapolated from thecAMP standard curve, according to the instructions provided in themanufacturer's user manual. Data were analyzed by nonlinear regressionanalysis with the GraphPad Prism Software package using the 3-parametersigmoidal dose-response model (slope constrained to unity). Potency dataare reported as pEC₅₀ values, the negative decadic logarithm of the EC₅₀value, where EC₅₀ is the effective concentration for a 50% maximalresponse.

Test compounds exhibiting a higher pEC₅₀ value in this assay have ahigher potency for agonizing the 5-HT₄ receptor. The compounds of theinvention which were tested in this assay, for example, in the cell line(1) having a density of about 0.5-0.6 pmol/mg protein, had a pEC₅₀ valueranging from about 7.5 to about 9.5.

Assay 4: In vitro Voltage Clamp Assay of Inhibition of Potassium IonCurrent in Whole Cells Expressing the hERG Cardiac Potassium Channel

CHO-K1 cells stably transfected with hERG cDNA were obtained from GailRobertson at the University of Wisconsin. Cells were held in cryogenicstorage until needed. Cells were expanded and passaged in Dulbecco'sModified Eagles Medium/F12 supplemented with 10% fetal bovine serum and200 μg/mL geneticin. Cells were seeded onto poly-D-lysine (100 μg/mL)coated glass coverslips, in 35 mm² dishes (containing 2 mL medium) at adensity that enabled isolated cells to be selected for whole cellvoltage-clamp studies. The dishes were maintained in a humidified, 5%CO₂ environment at 37° C.

Extracellular solution was prepared at least every 7 days and stored at4° C. when not in use. The extracellular solution contained (mM): NaCl(137), KCl (4), CaCl₂ (1.8), MgCl₂ (1), Glucose (10),4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid (HEPES) (10), pH 7.4with NaOH. The extracellular solution, in the absence or presence oftest compound, was contained in reservoirs, from which it flowed intothe recording chamber at approximately 0.5 mL/min. The intracellularsolution was prepared, aliquoted and stored at −20° C. until the day ofuse. The intracellular solution contained (mM): KCl (130), MgCl₂ (1),ethylene glycol-bis(beta-aminoethyl ether) N,N,N′,N′-tetra acetic acidsalt (EGTA) (5), MgATP (5),4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid (HEPES) (10), pH 7.2with KOH. All experiments were performed at room temperature (20-22°C.).

The coverslips on which the cells were seeded were transferred to arecording chamber and perfused continuously. Gigaohm seals were formedbetween the cell and the patch electrode. Once a stable patch wasachieved, recording commenced in the voltage clamp mode, with theinitial holding potential at −80 mV. After a stable whole-cell currentwas achieved, the cells were exposed to test compound. The standardvoltage protocol was: step from the holding potential of −80 mV to +20mV for 4.8 sec, repolarize to −50 mV for 5 sec and then return to theoriginal holding potential (−80 mV). This voltage protocol was run onceevery 15 sec (0.067 Hz). Peak current amplitudes during therepolarization phase were determined using pClamp software. Testcompounds at a concentration of 3 μM were perfused over the cells for 5minutes, followed by a 5-minute washout period in the absence ofcompound. Finally a positive control (cisapride, 20 nM) was added to theperfusate to test the function of the cell. The step from −80 mV to +20mV activates the hERG channel, resulting in an outward current. The stepback to −50 mV results in an outward tail current, as the channelrecovers from inactivation and deactivates.

Peak current amplitudes during the repolarization phase were determinedusing pCLAMP software. The control and test article data were exportedto Origin® (OriginLab Corp., Northampton Mass.) where the individualcurrent amplitudes were normalized to the initial current amplitude inthe absence of compound. The normalized current means and standarderrors for each condition were calculated and plotted versus the timecourse of the experiment.

Comparisons were made between the observed K⁺ current inhibitions afterthe five-minute exposure to either the test article or vehicle control(usually 0.3% DMSO). Statistical comparisons between experimental groupswere performed using a two-population, independent t-test (MicrocalOrigin v. 6.0). Differences were considered significant at p<0.05.

The smaller the percentage inhibition of the potassium ion current inthis assay, the smaller the potential for test compounds to change thepattern of cardiac repolarization when used as therapeutic agents. Forexample, the compounds of Examples 1-14 which were tested in this assayat a concentration of 3 μM exhibited an inhibition of the potassium ioncurrent of less than about 30%, including, less than about 20%.

Assay 5: In Vitro Model of Oral Bioavailability: Caco-2 Permeation Assay

The Caco-2 permeation assay was performed to model the ability of testcompounds to pass through the intestine and get into the blood streamafter oral administration. The rate at which test compounds in solutionpermeate a cell monolayer designed to mimic the tight junction of humansmall intestinal monolayers was determined.

Caco-2 (colon, adenocarcinoma; human) cells were obtained from ATCC(American Type Culture Collection; Rockville, Md.). For the permeationstudy, cells were seeded at a density of 63,000 cells/cm² on pre-wettedtranswells polycarbonate filters (Costar; Cambridge, Mass.). A cellmonolayer was formed after 21 days in culture. Following cell culture inthe transwell plate, the membrane containing the cell monolayer wasdetached from the transwell plate and inserted into the diffusionchamber (Costar; Cambridge, Mass.). The diffusion chamber was insertedinto the heating block which was equipped with circulating external,thermostatically regulated 37° C. water for temperature control. The airmanifold delivered 95% O₂/5% CO₂ to each half of a diffusion chamber andcreated a laminar flow pattern across the cell monolayer, which waseffective in reducing the unstirred boundary layer.

The permeation study was performed with test compound concentrations at100 μM and with ¹⁴C-mannitol to monitor the integrity of the monolayer.All experiments were conducted at 37° C. for 60 min. Samples were takenat 0, 30 and 60 min from both the donor and receiver sides of thechamber. Samples were analyzed by HPLC or liquid scintillation countingfor test compound and mannitol concentrations. The permeationcoefficient (K_(p)) in cm/sec was calculated.

In this assay, a K_(p) value greater than about 10×10⁻⁶ cm/sec isconsidered indicative of favorable bioavailability. Those compounds ofthe invention which were tested in this assay typically exhibited K_(p)values of between about 10×10⁻⁶ cm/sec and about 50×10⁻⁶ cm/sec.

Assay 6: Pharmacokinetic Study in the Rat

Aqueous solution formulations of test compounds were prepared in 0.1%lactic acid at a pH of between about 5 and about 6. Male Sprague-Dawleyrats (CD strain, Charles River Laboratories, Wilmington, Mass.) weredosed with test compounds via intravenous administration (IV) at a doseof 2.5 mg/kg or by oral gavage (PO) at a dose of 5 mg/kg. The dosingvolume was 1 mL/kg for IV and 2 mL/kg for PO administration. Serialblood samples were collected from animals pre-dose, and at 2 (IV only),5, 15, and 30 min, and at 1, 2, 4, 8, and 24 hours post-dose.Concentrations of test compounds in blood plasma were determined byliquid chromatography-mass spectrometry analysis (LC-MS/MS) (MDS SCIEX,API 4000, Applied Biosystems, Foster City, Calif.) with a lower limit ofquantitation of 1 ng/mL.

Standard pharmacokinetic parameters were assessed by non-compartmentalanalysis (Model 201 for IV and Model 200 for PO) using WinNonlin(Version 4.0.1, Pharsight, Mountain View, Calif.). The maximum in thecurve of test compound concentration in blood plasma vs. time is denotedC_(max). The area under the concentration vs. time curve from the timeof dosing to the last measurable concentration (AUC(0-t)) was calculatedby the linear trapezoidal rule. Oral bioavailability (F(%)), i.e. thedose-normalized ratio of AUC(0-t) for PO administration to AUC(0-t) forIV administration, was calculated as:F(%)=AUC_(PO)/AUC_(IV)×Dose_(IV)/Dose_(PO)×100%

Test compounds which exhibit larger values of the parameters C_(max),AUC(0-t), and F(%) in this assay are expected to have greaterbioavailability when administered orally. Preferred compounds of theinvention had C_(max) values typically ranging from about 0.06 to about0.8 μg/mL and AUC(0-t) values typically ranging from about 0.14 to about1.2 μg·hr/mL. By way of example, the compound of Example 1 had a C_(max)value of 0.8 μg/mL, an AUC(0-t) value of 1.2 μg·hr/mL and oralbioavailability (F(%)) in the rat model of about 75%.

While the present invention has been described with reference to thespecific embodiments thereof, it should be understood by those skilledin the art that various changes may be made and equivalents may besubstituted without departing from the true spirit and scope of theinvention. In addition, many modifications may be made to adapt aparticular situation, material, composition of matter, process, processstep or steps, to the objective, spirit and scope of the presentinvention. All such modifications are intended to be within the scope ofthe claims appended hereto. Additionally, all publications, patents, andpatent documents cited hereinabove are incorporated by reference hereinin full, as though individually incorporated by reference.

What is claimed is:
 1. A method of treating post-operative ileus in amammal comprising administering to the mammal, a therapeuticallyeffective amount of a compound of formula:

or a pharmaceutically acceptable salt thereof.
 2. The method of claim 1,wherein the mammal is a human.
 3. The method of claim 2, wherein theadministration is done parenterally.
 4. The method of claim 3, whereinthe administration is done through injection.
 5. The method of claim 3,wherein the administration is intravenous.
 6. The method of claim 2,wherein the compound is administered in a single daily dose.
 7. Themethod of claim 2, wherein the compound is administered in multipledoses per day.
 8. A method of treating post-operative ileus in a mammalcomprising administering to the mammal, a therapeutically effectiveamount of a compound of formula:


9. The method of claim 8, wherein the mammal is a human.
 10. The methodof claim 9, wherein the administration is done parenterally.
 11. Themethod of claim 10, wherein the administration is done throughinjection.
 12. The method of claim 10, wherein the administration isintravenous.
 13. The method of claim 9, wherein the compound isadministered in a single daily dose.
 14. The method of claim 9, whereinthe compound is administered in multiple doses per day.
 15. A method oftreating post-operative ileus in a mammal comprising administering tothe mammal, a therapeutically effective amount of a pharmaceuticalcomposition comprising a pharmaceutically-acceptable carrier and acompound of formula:

or a pharmaceutically acceptable salt thereof.
 16. The method of claim15, wherein the mammal is a human.
 17. The method of claim 16, whereinthe administration is done parenterally.
 18. The method of claim 17,wherein the administration is done through injection.
 19. The method ofclaim 17, wherein the administration is intravenous.
 20. The method ofclaim 16, wherein the pharmaceutical composition is administered in asingle daily dose.
 21. The method of claim 16, wherein thepharmaceutical composition is administered in multiple doses per day.